[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 121
1. Micke P, Kappert K, Ohshima M, Sundquist C, Scheidl S, Lindahl P, Heldin CH, Botling J, Ponten F, Ostman A: In situ identification of genes regulated specifically in fibroblasts of human basal cell carcinoma. J Invest Dermatol; 2007 Jun;127(6):1516-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ identification of genes regulated specifically in fibroblasts of human basal cell carcinoma.
  • Basal cell carcinoma (BCC) is characterized by slow growth, virtual absence of metastases, and strong stroma-dependency.
  • To comprehensively characterize CAFs of BCC in their in situ cancer environment, laser capture microdissection, linear gene amplification, microarray analysis, and quantitative real-time PCR (qRT-PCR) were combined.
  • Analyses of CAFs from squamous cell cancer, prostate cancer, and colon cancer did not indicate that these genes were upregulated in these cancers.
  • This study thus validates a novel approach for comprehensive characterization CAFs in their in situ environment of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Fibroblasts / physiology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273163.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Villani RM, Adolphe C, Palmer J, Waters MJ, Wainwright BJ: Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity. Cancer Prev Res (Phila); 2010 Oct;3(10):1222-34
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity.
  • Basal cell carcinoma (BCC) of the skin is the most common form of cancer, with the majority being caused by mutations in the Patched1 (Ptch1) gene, leading to activation of the Hedgehog (Hh) signaling pathway.
  • Here, we show that the key role of Ptch1 in the skin is to limit the size of the epidermal stem/progenitor compartment and allow hair follicle differentiation.
  • Specifically, loss of Ptch1 leads to the promotion of progenitor cell fate by increasing basal cell proliferation and limiting the progression of basal cells into differentiated hair follicle cell types.
  • We propose that Igfbp2 mediates epidermal progenitor cell expansion and therefore represents an epidermal progenitor cell-specific target of Hh signaling that promotes BCC development.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Cell Transformation, Neoplastic / genetics. Insulin-Like Growth Factor Binding Protein 2 / genetics. Receptors, Cell Surface / genetics. Skin Neoplasms / genetics. Stem Cells / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Proliferation. Epithelial Cells / metabolism. Epithelial Cells / pathology. Gene Expression. Gene Expression Profiling. Hair Follicle / pathology. Hedgehog Proteins / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Mice. Mice, Knockout. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / physiology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [CommentIn] Cancer Prev Res (Phila). 2010 Oct;3(10):1213-6 [20858762.001]
  • (PMID = 20858761.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


3. Hussain SK, Sundquist J, Hemminki K: The effect of having an affected parent or sibling on invasive and in situ skin cancer risk in Sweden. J Invest Dermatol; 2009 Sep;129(9):2142-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of having an affected parent or sibling on invasive and in situ skin cancer risk in Sweden.
  • Studies suggest that skin cancer aggregates within families; however, the risk of skin cancer associated with having an affected sibling or parent by subtype, tumor site, and age at diagnosis has not been established.
  • Risk of invasive squamous cell skin cancer for individuals with an affected sibling or parent was increased between two- and three-fold compared with that in the general population.
  • For in situ skin tumors, increased SIRs of 1.95-4.30 for squamous cell, Bowen's disease, and actinic keratosis were observed for individuals with affected siblings or parents, and SIRs were generally higher for tumors at sun-exposed versus covered sites.
  • Finally, SIRs for in situ and invasive squamous cell skin cancer increased by increasing number of parental tumors (P< or =0.01).
  • In conclusion, having an affected sibling or parent was associated with an increased risk of skin cancer of varied subtypes compared with that in the general population, and for some subtypes, these familial risks were increased for tumors at sun-exposed sites or by an increasing number of parental tumors.
  • [MeSH-major] Parents. Siblings. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Bowen's Disease / etiology. Bowen's Disease / genetics. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / genetics. Female. Humans. Male. Middle Aged. Sweden

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242514.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA 87949
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Ji J, Kump E, Wernli M, Erb P: Gene silencing of transcription factor Gli2 inhibits basal cell carcinomalike tumor growth in vivo. Int J Cancer; 2008 Jan 1;122(1):50-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene silencing of transcription factor Gli2 inhibits basal cell carcinomalike tumor growth in vivo.
  • Basal cell carcinoma (BCC) belongs worldwide to the most frequent malignancy among Caucasians.
  • The formation of sporadic BCCs in the skin is associated with uncontrolled hedgehog signaling, and the transcription factor Gli2 has been identified as a key mediator or effector of this signaling.
  • A constitutively Gli2 expressing mouse tumor cell line was stably transfected with Gli2-specific shRNA to induce Gli2 gene silencing or with control shRNA.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Silencing. Kruppel-Like Transcription Factors / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Apoptosis. HeLa Cells. Humans. In Situ Hybridization. In Situ Nick-End Labeling. Male. Mice. Mice, Nude. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17721996.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gli2 protein; 0 / Kruppel-Like Transcription Factors
  •  go-up   go-down


5. Tanese K, Fukuma M, Yamada T, Mori T, Yoshikawa T, Watanabe W, Ishiko A, Amagai M, Nishikawa T, Sakamoto M: G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol; 2008 Sep;173(3):835-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation.
  • The significance of Hedgehog (HH) signaling in the development of basal cell carcinoma (BCC) has been established.
  • Although several target genes of HH signaling have been described previously, their precise role in tumorigenesis and cell proliferation is not yet known.
  • Up-regulation of GPR49 was confirmed by in situ hybridization.
  • Moreover, knockdown of mouse Gpr49 showed suppression of cell proliferation in a mouse BCC cell line, and overexpression of GPR49 in human immortalized keratinocyte HaCaT cells induced proliferation.
  • In addition, inhibition of the HH signaling pathway in a mouse BCC cell line down-regulated endogenous Gpr49, whereas activation of HH signaling in mouse NIH3T3 cells up-regulated endogenous GPR49.
  • These results suggest that GPR49 is expressed downstream of HH signaling and promotes cell proliferation and tumor formation in cases of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Cell Proliferation. Receptors, G-Protein-Coupled / biosynthesis. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Gene Expression. Gene Expression Profiling. Hedgehog Proteins / physiology. Humans. In Situ Hybridization. Mice. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / physiology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2004 Nov;24(22):9736-43 [15509778.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5651-8 [15313903.001]
  • [Cites] Eur J Clin Invest. 1988 Feb;18(1):9-17 [3130266.001]
  • [Cites] Development. 1997 Apr;124(7):1313-22 [9118802.001]
  • [Cites] Am J Dermatopathol. 1997 Aug;19(4):341-50 [9261468.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1329-39 [16211229.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16239-44 [16258068.001]
  • [Cites] Cell. 2006 Jan 13;124(1):47-59 [16413481.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):419-26 [16575208.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6606-14 [16818633.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11623-31 [17178856.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1061-73 [17170733.001]
  • [Cites] ANZ J Surg. 2007 Jun;77(6):464-8 [17501888.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Arch Dermatol. 2000 Jul;136(7):937-8 [10891006.001]
  • [Cites] Mol Endocrinol. 2000 Aug;14(8):1257-71 [10935549.001]
  • [Cites] Chem Biol. 2000 Oct;7(10):793-803 [11033082.001]
  • [Cites] J Invest Dermatol. 2001 May;116(5):739-42 [11348463.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9255-9 [11481486.001]
  • [Cites] Cancer Lett. 2001 Nov 8;173(1):1-7 [11578802.001]
  • [Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]
  • [Cites] Hepatology. 2003 Mar;37(3):528-33 [12601349.001]
  • [Cites] Trends Endocrinol Metab. 2003 Sep;14(7):303-9 [12946872.001]
  • [Cites] Science. 2004 Jan 16;303(5656):359-63 [14671312.001]
  • [Cites] Nat Biotechnol. 2004 Apr;22(4):411-7 [15024388.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1180-7 [15140221.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • (PMID = 18688030.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / LGR5 protein, human; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled
  • [Other-IDs] NLM/ PMC2527081
  •  go-up   go-down


6. Basyuk E, Coulon V, Le Digarcher A, Coisy-Quivy M, Moles JP, Gandarillas A, Journot L: The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas. Mol Cancer Res; 2005 Sep;3(9):483-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas.
  • ZAC is a zinc finger transcription factor that induces apoptosis and cell cycle arrest in various cell lines.
  • ZAC expression is lost or down-regulated in some breast, ovary, and pituitary tumors and in an in vitro model of ovary epithelial cell transformation.
  • In the present study, we examined ZAC expression in normal skin and found a high expression level in basal keratinocytes and a lower, more heterogeneous, expression in the first suprabasal differentiating layers of epidermis.
  • Interestingly, we found a dramatic loss of ZAC expression in basal cell carcinoma, a neoplasm characterized by a relatively undifferentiated morphology.
  • In contrast, ZAC expression was maintained in squamous cell carcinomas that retain the squamous differentiated phenotype.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Cell Differentiation. Keratinocytes / cytology. Skin Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cells, Cultured. Genes, Tumor Suppressor. Humans. In Situ Hybridization. RNA Probes. Tumor Suppressor Proteins. Zinc Fingers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179495.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / PLAGL1 protein, human; 0 / RNA Probes; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


7. Teh MT, Blaydon D, Chaplin T, Foot NJ, Skoulakis S, Raghavan M, Harwood CA, Proby CM, Philpott MP, Young BD, Kelsell DP: Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res; 2005 Oct 1;65(19):8597-603
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event.
  • Basal cell carcinoma is the most common human cancer with increasing incidence reported worldwide.
  • Despite the aberrant signaling role of the Hedgehog pathway, little is known about the genetic mechanisms underlying basal cell carcinomas.
  • Towards a better understanding of global genetic events, we have employed the Affymetrix Mapping 10K single nucleotide polymorphism (SNP) microarray technique for "fingerprinting" genomewide allelic imbalance in 14 basal cell carcinoma-blood pair samples.
  • This rapid high-resolution SNP genotyping technique has revealed a somatic recombination event-uniparental disomy, leading to a loss of heterozygosity (LOH), as a key alternative genetic mechanism to allelic imbalances in basal cell carcinomas.
  • A highly conserved LOH region at 9q21-q31 was found in 13 of 14 (93%) basal cell carcinomas.
  • Further statistical and fluorescence in situ hybridization analyses confirmed that the 9q LOH was a result of uniparental disomy in 5 of 13 (38%) basal cell carcinomas.
  • De novo mutations in the Patched 1 gene (PTCH) were found in 9 of 13 (69%) basal cell carcinomas with 9q LOH.
  • A second important locus, containing LOH at 6q23-q27 was found in 5 of 14 (36%) basal cell carcinomas, suggesting that the presence of an additional putative tumor suppressor gene may be contributing to basal cell carcinoma development.
  • This study shows that the rate of 9q LOH in basal cell carcinomas has been previously underestimated.
  • Furthermore, we provide the first evidence that uniparental disomy due to somatic recombination constitutes one of the mechanisms of LOH in basal cell carcinoma tumorigenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Allelic Imbalance. Base Sequence. DNA Mutational Analysis. DNA, Neoplasm / genetics. Female. Genome, Human. Humans. Loss of Heterozygosity. Male. Middle Aged. Oligonucleotide Array Sequence Analysis / methods. Polymorphism, Single Nucleotide. Receptors, Cell Surface / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16204023.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


8. Zur Hausen A: [Merkel cell polyomavirus in the pathogenesis of non-melanoma skin cancer]. Pathologe; 2009 Dec;30 Suppl 2:217-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell polyomavirus in the pathogenesis of non-melanoma skin cancer].
  • [Transliterated title] Das Merkel-Zell-Polyomavirus in der Pathogenese nichtmelanozytärer Hauttumoren.
  • Merkel cell carcinoma (MCC) is a very aggressive neuroendocrine carcinoma of the skin.
  • The recently identified Merkel cell polyomavirus (MCPyV) is present in the majority of MCCs.
  • To elucidate a possible role of MCPyV in the pathogenesis of other non-melanoma skin cancers (NMSC), i.e. squamous cell carcinoma, Bowen's disease and basal cell carcinoma we tested a group of these tumors in immunosuppressed and immunocompetent patients.
  • Although MCPyV is present in the tumor cells of squamous cell carcinoma, Bowen's disease and basal cell skin carcinoma, further investigations into the role of MCPyV in the pathogenesis of these tumors is needed.
  • [MeSH-major] Bowen's Disease / genetics. Bowen's Disease / virology. Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / virology. Carcinoma, Merkel Cell / genetics. Carcinoma, Merkel Cell / virology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / virology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Viral / genetics. Merkel Cells / pathology. Merkel Cells / virology. Polyomavirus / genetics. Polyomavirus Infections / genetics. Polyomavirus Infections / virology. Skin Neoplasms / genetics. Skin Neoplasms / virology
  • [MeSH-minor] Antigens, Viral, Tumor / genetics. DNA Mutational Analysis. Genes, Viral / genetics. Humans. In Situ Hybridization, Fluorescence. Opportunistic Infections / genetics. Opportunistic Infections / pathology. Opportunistic Infections / virology. Polymerase Chain Reaction. Sequence Analysis, DNA. Skin / pathology. Skin / virology. Viral Load

  • Genetic Alliance. consumer health - Merkel cell cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1971 Jun 19;1(7712):1253-7 [4104714.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):246-8 [18650846.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Dec;8(4):310-5 [11127923.001]
  • [Cites] Proc Soc Exp Biol Med. 1953 Jun;83(2):414-21 [13064287.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):356-61 [19384948.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):217-24 [18070205.001]
  • [Cites] PLoS Pathog. 2007 May 4;3(5):e64 [17480120.001]
  • [Cites] JAMA. 2005 Sep 28;294(12):1476-80 [16189357.001]
  • [Cites] J Virol. 2007 Apr;81(8):4130-6 [17287263.001]
  • [Cites] J Natl Cancer Inst. 1968 Apr;40(4):867-73 [5646499.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1257-60 [4104715.001]
  • [Cites] Dev Biol Stand. 1998;94:183-90 [9776239.001]
  • [Cites] J Invest Dermatol. 2009 Dec;129(12):2868-74 [19554019.001]
  • [Cites] Proc Soc Exp Biol Med. 1960 Nov;105:420-7 [13774265.001]
  • [Cites] J Am Acad Dermatol. 1999 Aug;41(2 Pt 2):289-91 [10426911.001]
  • [Cites] J Pathol. 2009 May;218(1):48-56 [19291712.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5009-13 [18593898.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):107-10 [5009611.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):51-6 [17270666.001]
  • [Cites] J Invest Dermatol. 2007 Sep;127(9):2100-3 [17700621.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16272-7 [18812503.001]
  • [Cites] Emerg Infect Dis. 2009 Sep;15(9):1496-8 [19788824.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • (PMID = 19921198.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor
  •  go-up   go-down


9. Eshkoor SA, Ismail P, Rahman SA, Oshkour SA: p16 gene expression in basal cell carcinoma. Arch Med Res; 2008 Oct;39(7):668-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 gene expression in basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) develops predominantly in sun-exposed skin in fair-skinned individuals prone to sunburn.
  • In genetic studies, BCC patients have cell-cycle abnormalities of different parts of the signaling pathway.
  • Retinoblastoma regulatory pathway is important in cell cycle arrest.
  • Alteration of this pathway contributes to development of human cancers and also is effective in skin cancers.
  • In this study, we analyzed mRNA expression using in situ RT-PCR and the role of immunohistochemical expression of p16INK4a in BCC.
  • METHODS: Expression of p16 in ten samples of Iranian paraffin-embedded skin BCC were studied using in situ RT-PCR and immunohistochemistry on p16INK4a gene.
  • RESULTS: Nuclear and cytoplasmic staining intensity of samples within tumor cells and normal skin tissue illustrates different mRNA and protein expression of p16 gene. mRNA of p16 gene and the expressed protein induce cell cycle proliferation and involve both tumor tissue as well as normal skin tissue.
  • However, in this study it was found that there is significant protein and mRNA expression in BCC cells when compared to normal skin tissue (p<0.05).
  • CONCLUSIONS: p16 gene is involved in the pathogenesis of human skin BCC in view of increased p16 mRNA and expressed protein within tumor cells.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Genes, p16. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760195.001).
  • [ISSN] 0188-4409
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


10. Bäckvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F: Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res; 2005 Apr 1;571(1-2):65-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma.
  • Skin cancer provides an advantageous model for studying the development of cancer.
  • Detectable lesions occur early during tumor progression, facilitating molecular analysis of the cell populations from both preneoplastic and neoplastic lesions.
  • Alterations of the p53 tumor suppressor gene are very common in non-melanoma skin cancer, and dysregulation of p53 pathways appear to be an early event in the tumor development.
  • A high frequency of epidermal p53 clones has been detected in chronically sun-exposed skin.
  • The abundance of clones containing p53 mutated keratinocytes adjacent to basal cell (BCC) and squamous cell carcinoma (SCC) suggests a role in human skin carcinogenesis.
  • Studies using p53 mutations as a clonality marker have suggested a direct link between actinic keratosis, SCC in situ and invasive SCC.
  • Here, we present examples of using well-defined cell populations, including single cells, from complex tissue in combination with molecular tools to reveal features involved in skin carcinogenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Genetic Heterogeneity. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748639.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 79
  •  go-up   go-down


11. Prignano F, Lotti T, Spallanzani A, Berti S, de Giorgi V, Moretti S: Sequential effects of photodynamic treatment of basal cell carcinoma. J Cutan Pathol; 2009 Apr;36(4):409-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential effects of photodynamic treatment of basal cell carcinoma.
  • BACKGROUND: Photodynamic therapy (PDT) of superficial basal cell carcinoma (SBCC) acts as a biological response modifier or killing target cells, but sequential biological effects have not been reported in depth in humans.
  • At baseline, SBCC cells expressed stem cell factor in all cases, and granulocyte-monocyte colony-stimulating factor, basic fibroblastic growth factor, interleukin (IL)-8 and vascular endothelial growth factor in most cases.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Cytokines / drug effects. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Inflammation / chemically induced. Inflammation / immunology. Inflammation / pathology. Microscopy, Electron, Transmission. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278425.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cytokines; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


12. Newman MD, Weinberg JM: Topical therapy in the treatment of actinic keratosis and basal cell carcinoma. Cutis; 2007 Apr;79(4 Suppl):18-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical therapy in the treatment of actinic keratosis and basal cell carcinoma.
  • AK also is known as solar keratosis and squamous cell carcinoma (SCC) in situ, either solar keratotic type or keratinocytic intraepidermal neoplasia.
  • Topical treatment of basal cell carcinoma (BCC) with imiquimod also will be discussed.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508492.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclooxygenase Inhibitors; 0 / Retinoids; 0 / Tubulin Modulators
  • [Number-of-references] 44
  •  go-up   go-down


13. Imiquimod for superficial and in situ skin malignancy. Drug Ther Bull; 2009 Oct;47(10):113-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod for superficial and in situ skin malignancy.
  • Imiquimod, an immune response modifier, is marketed as Aldara 5% cream (Meda) and licensed for treating adults with small superficial basal cell carcinomas (BCCs).1 Numerous uses outside the licensed indications (i.e.
  • 'off-label') have been proposed and practised, including as treatment for pre-cancerous conditions such as Bowen's disease (squamous cell carcinoma in situ) and lentigo maligna (an in situ precursor of melanoma).2,3 Here we review the use of imiquimod for small superficial primary BCC in adults, Bowen's disease and lentigo maligna.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19809085.001).
  • [ISSN] 0012-6543
  • [Journal-full-title] Drug and therapeutics bulletin
  • [ISO-abbreviation] Drug Ther Bull
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 26
  •  go-up   go-down


14. Wagoner J, Keehn C, Morgan MB: CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma. Am J Dermatopathol; 2007 Dec;29(6):555-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma.
  • Basal cell carcinoma and squamous cell carcinoma are common entities in clinical practice.
  • We sought to determine if the CD10 immunostain could have diagnostic utility in distinguishing between early superficial basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • CD10 was negative in the tumor cells in 13 out of 13 superficially invasive SCCs and SCC in situ.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neprilysin / analysis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032951.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


15. Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, Andrew A, Green AC, Bavinck JN, Perry A, Spencer S, Rees JR, Mott LA, Pawlita M: Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst; 2006 Mar 15;98(6):389-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin.
  • BACKGROUND: Although infection with human papillomaviruses (HPVs) is a major risk factor for several epithelial cancers, an etiologic relationship between HPV and keratinocyte cancers, such as squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs), remains unclear.
  • Multiplex serology is a new method that is based on fluorescent bead technology and allows simultaneous detection of antibodies against up to 100 different in situ affinity-purified recombinant HPV proteins.
  • [MeSH-major] Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / virology. Papillomaviridae. Papillomavirus Infections / complications. Skin Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Oct 4;98(19):1425-6 [17018790.001]
  • (PMID = 16537831.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57494
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Freier K, Flechtenmacher C, Devens F, Hartschuh W, Hofele C, Lichter P, Joos S: Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma. Oncol Rep; 2006 May;15(5):1141-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma.
  • Formation of basal cell carcinoma (BCC) has been linked to deregulation in the sonic hedgehogh (Shh) signalling pathway.
  • To assess the expression of Nmyc protein and gene copy numbers of the NMYC gene locus in a representative BCC tumour collection, immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) were performed on 273 BCC specimens of different growth patterns and anatomic localisations on tissue microarray (TMA) sections.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Dosage. Genes, myc / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Case-Control Studies. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Skin / metabolism. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596176.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


17. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR).
  • : 1519 Background: Skin cancers are the most common malignancies in OTR.
  • Topical 5% 5-FU has been used to successfully treat squamous cell carcinoma (SCC) in situ and actinic keratosis (AK).
  • Capecitabine, an orally-administered prodrug of 5-FU, in combination with interferon was shown to be effective in the treatment of advanced SCC of the skin.
  • This study was to determine the efficacy of low-dose capecitabine in secondary prevention of the skin cancers in OTR.
  • METHODS: OTR who developed recurrent skin cancers, SCC, and/or basal cell carcinoma (BCC), were given low-dose capecitabine 1g/m2 divided in two daily doses, day 1-14 of 21-day treatment cycle.
  • Skin surveillances were performed by dermatologists every 1 to 3 months.
  • Age and the number of transplants were not significantly related to the change in incidence rates for all skin lesion types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Goldberg LH, Kimyai-Asadi A: Diffuse epidermal and periadnexal squamous cell carcinoma in situ: a report of 13 patients. J Am Acad Dermatol; 2005 Oct;53(4):623-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse epidermal and periadnexal squamous cell carcinoma in situ: a report of 13 patients.
  • BACKGROUND: Diffuse epidermal and periadnexal squamous cell carcinoma in situ (DEPS) is a condition in which large areas of skin are affected by atypical keratinocytes that grow beneath the epidermis and encase adnexal epithelia.
  • In the 52 cumulative patient-years of follow-up, we treated 80 invasive squamous cell and 48 basal cell carcinomas in these patients.
  • CONCLUSION: DEPS is characterized by diffuse involvement of chronically sun-exposed skin with atypical keratinocytes that grow along the inferior portion of the basal layer of the epidermis and around adnexal structures.
  • DEPS is also associated with the development of invasive squamous cell and basal cell carcinomas.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Epidermis / pathology. Facial Neoplasms / pathology. Keratinocytes / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198782.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Love WE, Bernhard JD, Bordeaux JS: Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol; 2009 Dec;145(12):1431-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
  • OBJECTIVES: To conduct a systematic review to determine clearance rates and adverse effects of topical imiquimod or fluorouracil therapy in the treatment of nonmelanoma skin cancers such as basal (BCC) and squamous cell carcinoma (SCC), and to develop recommendations for the use of topical imiquimod or fluorouracil to treat BCC and SCC.
  • DATA EXTRACTION: We calculated the rate of clearance and adverse effects for BCC subtypes and invasive and in situ SCC treated with topical imiquimod or fluorouracil.
  • Imiquimod use produced the following clearance rates: 43% to 100% for superficial BCC, 42% to 100% for nodular BCC, 56% to 63% for infiltrative BCC, 73% to 88% for SCC in situ, and 71% for invasive SCC.
  • Fluorouracil use produced the following clearance rates: 90% for superficial BCC and 27% to 85% for SCC in situ.
  • CONCLUSIONS: Evidence supports the use of topical imiquimod as monotherapy for superficial BCC and topical fluorouracil as monotherapy for superficial BCC and SCC in situ.
  • [MeSH-major] Aminoquinolines / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Fluorouracil / pharmacokinetics. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026854.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 47
  •  go-up   go-down


20. King R, Lyons J, Meyers AL, Googe PB, Page RN, Gupta VK: Primary invasive melanoma and basal cell carcinoma (collision tumor) with blue nevus-like cutaneous metastases. J Cutan Pathol; 2007 Aug;34(8):629-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary invasive melanoma and basal cell carcinoma (collision tumor) with blue nevus-like cutaneous metastases.
  • The juxtaposition of malignant melanoma and basal cell carcinoma (BCC) has been rarely reported in case reports, with most cases describing melanoma in situ and BCC.
  • Immunohistochemical studies delineated the two cell populations.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Blue / secondary. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640233.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


21. Kanner WA, Galgano MT, Atkins KA: Podoplanin expression in basal and myoepithelial cells: utility and potential pitfalls. Appl Immunohistochem Mol Morphol; 2010 May;18(3):226-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Podoplanin expression in basal and myoepithelial cells: utility and potential pitfalls.
  • We evaluated the expression of D2-40 in breast, salivary gland, skin, and mucosa, all organs rich in myoepithelial cells and basal cells.
  • This study assessed the utility of using D2-40 to highlight basal/myoepithelial cells and to identify potential pitfalls in misinterpretation of lymphatic invasion.
  • Our results showed that myoepithelial cells in breast and salivary gland and basal cells in prostate consistently demonstrate D2-40 immunoreactivity, but typically less intensely than lymphatics.
  • Cutaneous and mucosal-based basal cells also have D2-40 expression, but often in a patchy, focal manner.
  • In addition, many salivary gland tumors and squamous cell carcinomas had strong D2-40 expression, sometimes making distinction of lymphatics versus tumor edge staining difficult.
  • D2-40 is excellent for assessing lymphatic invasion in breast, prostate, and cervix as long as the pathologist is aware of the expression in myoepithelial cells/basal cells to avoid misinterpretation of ductal carcinoma in situ or normal prostate glands or tumor stroma retraction as tumor lymphatic invasion.
  • Given the patchy positivity in basal cells of skin and mucosa and the reactivity in squamous cell carcinoma, D2-40 was not helpful in assessing for microinvasion of squamous cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20042851.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Membrane Glycoproteins; 0 / PDPN protein, human
  •  go-up   go-down


22. Saglam O, Salama M, Meier F, Chaffins M, Ma C, Ormsby A, Lee M: Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin. Am J Dermatopathol; 2008 Apr;30(2):123-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin.
  • Actinic keratosis (AK) and Bowen's disease (BD) are common patterns of in situ squamous cell carcinoma of the epidermis.
  • In AK, atypical keratinocytes proliferate in the lower portion of the epidermis including the basal layer.
  • In contrast, BD features atypical squamous cells in all portions of the epidermis but initially leaves basal cells in palisades along the basement membrane.
  • To characterize immunohistochemically keratocyte proliferation in AK and Palisading Basal Cells (PBC) in BD, we stained microarray samples of 45 AK and 25 BD with Molecular Immunology Borstel (MIB-1).
  • Subsequent immunostaining of full mounted sections examined 11 BD, 7 AK, and 4 examples of psoriasis for MIB-1 (as a proliferative marker) and p53 (as a cell cycle regulatory marker).
  • AK stained for MIB-1 and p53 antibodies only in lower portion of epidermis and included the basal layer.
  • BD with typical PBCs stained positive for both markers throughout the epidermis, except for the basal layer.
  • Psoriatic biopsies stained positively for the 2 markers only in the basal and parabasal layers.
  • Normal epidermis adjacent to the lesions in AK and BD biopsies stained sparsely in the basal layers.
  • Lack of expression of proliferative antigens in palisading basal cells in BD provides evidence that PBCs are not the cell of origin for BD.
  • Conversely in AK, expression of MIB-1 and p53 in basal cells argues that these cells play a role in histogenesis of AK.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma, Basal Cell / pathology. Keratosis / pathology. Ki-67 Antigen / metabolism. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360114.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Suciu V, Botan E, Valent A, Chami L, Spatz A, Vielh P: The potential contribution of fluorescent in situ hybridization analysis to the cytopathological diagnosis of Merkel cell carcinoma. Cytopathology; 2008 Feb;19(1):48-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential contribution of fluorescent in situ hybridization analysis to the cytopathological diagnosis of Merkel cell carcinoma.
  • We report the cases of two patients with head and neck Merkel cell carcinoma (MCC) who developed local recurrences confirmed by cytopathology.
  • Interphase fluorescent in situ hybridization (FISH) analysis was performed for research purposes using centromeric probes of chromosomes 6 and 8, on cytological slides.
  • [MeSH-major] Carcinoma, Merkel Cell / genetics. In Situ Hybridization, Fluorescence. Neoplasm Recurrence, Local / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Fine-Needle. Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Chromosomes, Human, Pair 6 / genetics. Chromosomes, Human, Pair 8 / genetics. Female. Humans. Immunohistochemistry. Male. Neoplasms, Second Primary / genetics. Neoplasms, Second Primary / pathology. Trisomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205628.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Perrem K, Lynch A, Al Nooh F, Leader M, Elaine Kay: The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population. Hum Pathol; 2008 Jul;39(7):1034-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population.
  • Renal transplant recipients incur markedly higher rates of nonmelanoma skin cancer, including both basal and squamous cell carcinoma, by unknown mechanisms that are thought to be activated by long-term immunosuppression.
  • These tumors typically arise in sun-exposed areas of the skin and are biologically more aggressive in renal transplant recipients compared with nontransplant patients.
  • Interestingly also, the incidence of squamous cell carcinoma is generally 2- to 3-fold higher than that of basal cell carcinoma in renal transplant recipients, which is a reversal of the trend in the nontransplant population.
  • We have shown in a previous report that the increased incidence of squamous cell carcinoma in renal transplant patients is characterized by increased telomere lengths when compared with the same tumors in the nontransplant population.
  • In our current study, we performed a similar analysis of a cohort of 35 basal cell carcinoma samples from both the renal transplant and nontransplant patient groups.
  • We find that, in contrast to the situation in squamous cell carcinoma, the telomeres of the basal cell carcinomas in renal transplant recipients are in fact shorter than their counterparts in the nontransplant population, but also that these lengths are considerably longer in both cases than their squamous cell counterparts.
  • This is the first report to comprehensively show that the telomere lengths significantly differ between basal and squamous cell carcinomas.
  • These data also suggest that future treatment strategies for nonmelanoma skin cancers that are based upon telomerase inhibition, including those arising in transplant patients, may require different approaches for these two different skin lesions.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Kidney Transplantation. Skin Neoplasms / pathology. Telomere / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Immunocompromised Host. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482746.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Fantini F, Greco A, Cesinaro AM, Surrenti T, Peris K, Vaschieri C, Marconi A, Giannetti A, Pincelli C: Pathologic changes after photodynamic therapy for Basal cell carcinoma and Bowen disease: a histologic and immunohistochemical investigation. Arch Dermatol; 2008 Feb;144(2):186-94
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic changes after photodynamic therapy for Basal cell carcinoma and Bowen disease: a histologic and immunohistochemical investigation.
  • OBJECTIVE: To investigate the in vivo reactions and the mechanisms of cell death after photodynamic therapy (PDT) for cutaneous carcinomas.
  • Photodynamic therapy is a new treatment modality for nonmelanoma skin cancers.
  • DESIGN: Skin biopsy specimens were obtained sequentially after PDT for basal cell carcinoma and in situ squamous cell carcinoma (Bowen disease).
  • We used electron microscopy to evaluate cell damage at the ultrastructural level.
  • MAIN OUTCOME MEASURES: Evidence of the mechanisms of tumor cell damage after PDT, detection of histologic and/or immunohistochemical signs of apoptosis, and time course of the tumor destruction and inflammatory reaction.
  • In basal cell carcinoma, nodule damage progressed from scant apoptotic cells seen at the dermal-epithelial junction to massive destruction seen after 1 and 2 days.
  • CONCLUSIONS: This study defines the time course and characteristics of the skin tumor response to PDT.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Apoptosis. Biopsy. Caspase 3 / metabolism. Enzyme Activation. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Male. Microscopy, Electron. Middle Aged. Photosensitizing Agents / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283175.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


26. Belisle A, Gautier MS, Ghozali F, Plantier F, Wechsler J: A collision tumor involving Basal cell carcinoma and lentigo maligna melanoma. Am J Dermatopathol; 2005 Aug;27(4):319-21
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A collision tumor involving Basal cell carcinoma and lentigo maligna melanoma.
  • Basal cell carcinomas (BCC) are known to co-exist with other cutaneous lesions, but the collision of BCC with malignant melanoma is rare.
  • Histologic examination showed lesions of lentigo maligna melanoma (LMM) in situ and invasive melanoma involving nests of BCC that invaded the dermis.
  • On examination of the biopsy specimen, melanoma was still in situ because it was limited to the nests of BCC and not detectable between dermal collagen bundles.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Hutchinson's Melanotic Freckle / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121053.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Su W, Kheir SM, Berberian B, Cockerell CJ: Merkel cell carcinoma in situ arising in a trichilemmal cyst: a case report and literature review. Am J Dermatopathol; 2008 Oct;30(5):458-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma in situ arising in a trichilemmal cyst: a case report and literature review.
  • Histological examination showed a trichilemmal cyst with 3 nests of small blue round cells within the basal layer of the cyst lining.
  • The stain for cytokeratin 20 "decorated" the tumor cells with an unequivocal perinuclear dot-like pattern, confirming their Merkel cell origin.
  • Dermal Merkel cell carcinoma (MCC) arising in association with benign adnexal tumors or cysts, with or without epithelial involvement, is a rare event.
  • MCC in situ in this context has not been previously reported.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18806489.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-20
  • [Number-of-references] 46
  •  go-up   go-down


28. Aractingi S, Kanitakis J, Euvrard S, Le Danff C, Peguillet I, Khosrotehrani K, Lantz O, Carosella ED: Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res; 2005 Mar 1;65(5):1755-60
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin carcinoma arising from donor cells in a kidney transplant recipient.
  • The incidence of skin cancer is increased in transplant recipients.
  • Herein, we investigated the possible involvement of donor cells in the development of skin tumors in kidney allograft recipients.
  • In the samples with high levels of male cells, fluorescent in situ hybridization (FISH) with X and Y probes and/or immuno-FISH with anticytokeratin antibodies were carried out.
  • Male cells were detected in 5/15 squamous cell carcinomas and Bowen disease (range 4-180 copies), 3/5 basal cell carcinomas (91-645), 6/11 actinic keratosis (7-102), 2/4 keratoacanthoma (22-41), and 2/5 benign cutaneous lesions (14-55).
  • In a basal cell carcinoma specimen with a high number of male cells, FISH showed that most cells within the tumoral buds were XY.
  • In conclusion, stem cells originating from a grafted kidney may migrate to the skin, differentiate, or fuse as keratinocytes that could, rarely, undergo cancer transformation.
  • [MeSH-major] Kidney Transplantation / adverse effects. Skin Diseases / etiology. Skin Neoplasms / etiology. Stem Cells / pathology. Tissue Donors
  • [MeSH-minor] Bowen's Disease / etiology. Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Cell Differentiation. Cell Fusion. Chromosomes, Human, X / genetics. Chromosomes, Human, Y / genetics. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Karyotyping. Keratinocytes / cytology. Keratinocytes / metabolism. Keratins / metabolism. Keratoacanthoma / etiology. Keratosis / etiology. Male. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Homologous


29. Mogensen M, Jemec GB: Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies. Dermatol Surg; 2007 Oct;33(10):1158-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies.
  • BACKGROUND: Nonmelanoma skin cancer (NMSC) is the most prevalent cancer in the light-skinned population.
  • OBJECTIVE: The scope of this review is to present data on the current state-of-the-art diagnostic methods for keratinocyte carcinoma: basal cell carcinoma, squamous cell carcinoma, and actinic keratosis.
  • CONCLUSIONS: Some of these new imaging technologies have the capability of providing new, three-dimensional in vivo, in situ understanding of NMSC development over time.
  • [MeSH-major] Skin Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / ultrasonography. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / ultrasonography. Dermoscopy. Diagnostic Tests, Routine. Humans. Keratosis / diagnosis. Keratosis / pathology. Keratosis / ultrasonography

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903149.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 128
  •  go-up   go-down


30. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol; 2005 Jun;52(6):997-1002
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery.
  • BACKGROUND: Bowen's disease (BD), also known as squamous intraepidermal carcinoma, is a malignant skin tumor with a potential to progress to invasive carcinoma.
  • METHODS: This prospective, multicenter, case series included all patients in Australia treated with MMS for BD, who were monitored by the Skin and Cancer Foundation between 1993 and 2002.
  • In 20% the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.
  • [MeSH-major] Bowen's Disease / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928618.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


31. Dadzie OE, Goerig R, Bhawan J: Incidental microscopic foci of nevic aggregates in skin. Am J Dermatopathol; 2008 Feb;30(1):45-50
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental microscopic foci of nevic aggregates in skin.
  • The nevic aggregates were separate and located in normal skin, away from any associated tumors or scar tissue.
  • The purpose of this study is to draw attention to the existence of incidental cutaneous nevic aggregates, thereby alerting pathologists and dermatopathologists to their potential as a diagnostic pitfall, especially in the setting of concurrent primary cutaneous malignant melanoma or melanoma in situ.
  • [MeSH-major] Incidental Findings. Melanocytes / pathology. Nevus / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Male. Melanoma / pathology. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2008 Aug;30(4):403-6 [18645318.001]
  • (PMID = 18212544.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE, Lobo-Ruppert SM, Ruppert JM: Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene; 2005 Feb 24;24(9):1491-500
eagle-i research resources. PMID 15674344 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.
  • To examine the role of this zinc finger protein in skin, we expressed the wild-type human allele from inducible and constitutive promoters.
  • When induced in basal keratinocytes, KLF4 rapidly abolished the distinctive properties of basal and parabasal epithelial cells.
  • KLF4 caused a transitory apoptotic response and the skin progressed through phases of hyperplasia and dysplasia.
  • By 6 weeks, lesions exhibited nuclear KLF4 and other morphologic and molecular similarities to squamous cell carcinoma in situ. p53 determined the patch size sufficient to establish lesions, as induction in a mosaic pattern produced skin lesions only when p53 was deficient.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26737-40 [11389134.001]
  • [Cites] Cancer Surv. 1998;32:69-113 [10489624.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):778-84 [11698196.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Development. 2002 Jun;129(11):2619-28 [12015290.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):998-1002 [12060394.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S2-9 [11684435.001]
  • [Cites] Nucleic Acids Res. 1999 Dec 1;27(23):4562-9 [10556311.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18391-8 [10749849.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):37798-806 [10954723.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6488-95 [11103818.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5867-73 [12384550.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11661-9 [12538588.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):203-5 [12676578.001]
  • [Cites] Development. 2003 Jun;130(12):2767-77 [12736219.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3424-30 [12776194.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):763-70 [14644203.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jan;286(1):G23-30 [12919939.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):425-9 [14706334.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):395-402 [14724568.001]
  • [Cites] Cell. 2004 Jan 23;116(2):235-46 [14744434.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):311-6 [15093538.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2709-19 [15102675.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3815-24 [15173090.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Cell Sci. 1987 Oct;88 ( Pt 3):305-12 [3129440.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3713-21 [2660980.001]
  • [Cites] Cell Differ Dev. 1990 Apr;30(1):27-34 [2350734.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1147-55 [2161707.001]
  • [Cites] Nature. 1991 Jul 25;352(6333):345-7 [1852210.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Cell. 1993 Sep 10;74(5):813-22 [8374952.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] J Virol. 1994 Jul;68(7):4358-68 [7515971.001]
  • [Cites] Nature. 1994 Dec 22-29;372(6508):773-6 [7997263.001]
  • [Cites] Nucleic Acids Res. 1995 May 25;23(10):1686-90 [7784172.001]
  • [Cites] Cancer Metastasis Rev. 1995 Jun;14(2):113-24 [7554029.001]
  • [Cites] Methods Enzymol. 1995;254:3-20 [8531694.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1621-5 [8658135.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] J Cell Biochem. 1995 Dec;59(4):463-72 [8749716.001]
  • [Cites] J Biol Chem. 1996 Aug 16;271(33):20009-17 [8702718.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31384-90 [8940147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9 [8943054.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(8):376-83 [9332893.001]
  • [Cites] FEBS Lett. 1997 Dec 15;419(2-3):239-43 [9428642.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10747-54 [9553140.001]
  • [Cites] J Biol Chem. 1998 Jul 10;273(28):17917-25 [9651398.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):469-86 [9786956.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:111-22 [9893262.001]
  • [Cites] Oncogene. 1999 Jun 17;18(24):3593-607 [10380881.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):423-34 [10392904.001]
  • [Cites] Nat Genet. 1999 Aug;22(4):356-60 [10431239.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • (PMID = 15674344.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30CA13148; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / P30 CA013148; United States / NCI NIH HHS / CA / R01 CA094030; United States / NCI NIH HHS / CA / R29 CA065686; United States / NCI NIH HHS / CA / CA89019; United States / NCI NIH HHS / CA / R01 CA065686; United States / NCI NIH HHS / CA / CA65686; United States / NCI NIH HHS / CA / CA094030
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / Transcription Factors; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS7908; NLM/ PMC1361530
  •  go-up   go-down


33. Qiao W, Li AG, Owens P, Xu X, Wang XJ, Deng CX: Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. Oncogene; 2006 Jan 12;25(2):207-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin.
  • To study the role of Smad4 in skin development and epidermal tumorigenesis, we disrupted this gene in skin using the Cre-loxP approach.
  • Additionally, the skin of MT mice exhibited increased proliferation of basal keratinocytes and epidermal hyperplasia.
  • Consequently, all MT mice developed spontaneous malignant skin tumors from 3 months to 13 months of age.
  • The majority of tumors are malignant squamous cell carcinomas.
  • These observations revealed the essential functions of Smad4-mediated signals in repressing skin tumor formation through the TGFbeta/BMP pathway, which interacts with the Pten signaling pathway.
  • [MeSH-major] Alopecia / genetics. Carcinoma, Squamous Cell / genetics. Cell Differentiation. Hair Follicle / abnormalities. Signal Transduction. Skin Neoplasms / genetics. Smad4 Protein / physiology
  • [MeSH-minor] Animals. Bone Morphogenetic Proteins / metabolism. Cell Nucleus / metabolism. Cell Proliferation. Cyclin D1 / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Enzyme Activation. Epidermis / pathology. Female. Hyperplasia / etiology. In Situ Hybridization. Integrases. Keratinocytes / cytology. Keratinocytes / metabolism. Male. Mice. Mice, Knockout. Mice, Transgenic. PTEN Phosphohydrolase / antagonists & inhibitors. PTEN Phosphohydrolase / metabolism. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / embryology. Skin / growth & development. Transforming Growth Factor beta / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170355.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR47898; United States / NCI NIH HHS / CA / CA87849
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Morphogenetic Proteins; 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Messenger; 0 / Smad4 Protein; 0 / Smad4 protein, mouse; 0 / Transforming Growth Factor beta; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


34. Malvehy J, Puig S, Martí-Laborda RM: Dermoscopy of skin lesions in two patients with xeroderma pigmentosum. Br J Dermatol; 2005 Feb;152(2):271-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy of skin lesions in two patients with xeroderma pigmentosum.
  • The early diagnosis of malignant skin tumours is crucial in the survival of patients with XP, but this is not easy even for experienced dermatologists due to the presence of a high number of actinic lesions.
  • Dermoscopy is a new diagnostic method that increases the diagnostic accuracy for skin tumours.
  • OBJECTIVES: To describe the clinical and dermoscopic features of different benign and malignant lesions [focusing on malignant melanoma, basal cell carcinoma (BCC) and benign melanocytic naevi] in two patients with XP.
  • METHODS: Three dermatologists with experience in pigmented skin lesions and dermoscopy examined two siblings with XP over a period of 54 months.
  • Diagnosis of skin tumours was obtained using clinical examination and dermoscopy with 10-fold magnification and digital images.
  • RESULTS: Multiple skin tumours showing some degree of pigmentation were detected in the patients.
  • Clinical and dermoscopic examination allowed the discrimination of four melanomas (three of them in situ), 26 BCCs and five dysplastic naevi from other pigmented skin lesions.
  • [MeSH-major] Dermoscopy. Skin Neoplasms / diagnosis. Skin Neoplasms / etiology. Xeroderma Pigmentosum / complications
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / etiology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Melanoma / diagnosis. Melanoma / etiology. Nevus, Pigmented / diagnosis. Nevus, Pigmented / etiology

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15727638.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA83115
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


35. Yu HS, Liao WT, Chai CY: Arsenic carcinogenesis in the skin. J Biomed Sci; 2006 Sep;13(5):657-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic carcinogenesis in the skin.
  • Long-term exposure to inorganic arsenic (As) from drinking water has been documented to induce cancers in lung, urinary bladder, kidney, liver and skin in a dose-response relationship.
  • Arsenic tends to accumulate in the skin.
  • Skin hyperpigmentation and hyperkeratosis have long been known to be the hallmark signs of chronic As exposure.
  • There are significant associations between these dermatological lesions and risk of skin cancer.
  • The most common arsenic-induced skin cancers are Bowen's disease (carcinoma in situ), basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • Arsenic exposure is associated with G2/M cell cycle arrest and DNA aneuploidy in both cultured keratinocytes and As-BD lesions.
  • The characteristic clinical figures of arsenic-induced skin cancer are: (i) occurrence on sun-protected areas of the body;.
  • Both As and UVB are able to induce skin cancer.
  • As-UVB interaction provides a reasonable explanation for the rare occurrences of arsenical cancer in the sun-exposed skin.
  • The multiple and recurrent skin lesions are associated with cellular immune dysfunction in chronic arsenism.
  • Since CD4+ cells are the target cell affected by As, the interaction between CD4+ cells and epidermal keratinocytes under As affection might be closely linked to the pathogenesis of multiple occurrence of arsenic-induced skin cancer.
  • In this review, we provide and discuss the pathomechanisms of arsenic skin cancer and the relationship to its characteristic figures.
  • [MeSH-major] Arsenic / toxicity. Neoplasms, Glandular and Epithelial / etiology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807664.001).
  • [ISSN] 1021-7770
  • [Journal-full-title] Journal of biomedical science
  • [ISO-abbreviation] J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0 / Transcription Factors; N712M78A8G / Arsenic
  • [Number-of-references] 110
  •  go-up   go-down


36. Brewster DH, Bhatti LA, Inglis JH, Nairn ER, Doherty VR: Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992-2003. Br J Dermatol; 2007 Jun;156(6):1295-300
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992-2003.
  • BACKGROUND: Historically, ascertainment of nonmelanoma skin cancer (NMSC) by cancer registries in the U.K. has been shown to be incomplete in several studies.
  • OBJECTIVES: To assess recent trends in incidence of the main types of NMSC and carcinoma in situ (CIS) of the skin in Scotland.
  • Incident cases of squamous cell carcinoma (SCC) of the skin, CIS of the skin, and first ever basal cell carcinoma (BCC) were extracted from the Scottish Cancer Registry covering the period of diagnosis 1992-2003.
  • The percentage distribution of SCC, BCC and CIS of the skin by anatomical site and sex was calculated for the period of diagnosis 1997-2003.
  • Age-adjusted rates of SCC, first ever BCC, and CIS of the skin have all increased significantly in both sexes between 1992 and 2003 (all P < 0.001), with EAPCs ranging in magnitude from +1.4% (first ever BCC in males) to +5.1% (CIS in males).
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535229.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Wollina U, Nelskamp C, Scheibe A, Fassler D, Schmidt WD: Fluorescence--remission sensoring of skin tumours: preliminary results. Skin Res Technol; 2007 Nov;13(4):463-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence--remission sensoring of skin tumours: preliminary results.
  • OBJECTIVE: Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in men.
  • PATIENTS AND METHODS: Because the simultaneous measurement of fluorescence and remission of skin is impossible, a principle of subsequent measurement of remission and fluorescence had been developed by our group.
  • Using this technology, we performed a pilot study in 19 patients with 30 NMSC-suspicious lesions including: actinic keratosis (n=10), basal cell carcinoma (BCC; n=16) and squamous cell carcinoma (SCC; n=4 with two in situ carcinomas).
  • CONCLUSIONS: A combination of fluorescence and remission readings of skin provides objective data in NMSC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratosis / pathology. Skin Neoplasms / pathology. Spectroscopy, Near-Infrared / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Dermatology / instrumentation. Dermatology / methods. Dermoscopy. Diagnosis, Differential. Female. Fluorescence. Humans. Male. Pilot Projects. Reproducibility of Results. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908200.001).
  • [ISSN] 0909-752X
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


38. Hartmann-Petersen S, Tammi RH, Tammi MI, Kosma VM: Depletion of cell surface CD44 in nonmelanoma skin tumours is associated with increased expression of matrix metalloproteinase 7. Br J Dermatol; 2009 Jun;160(6):1251-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depletion of cell surface CD44 in nonmelanoma skin tumours is associated with increased expression of matrix metalloproteinase 7.
  • We previously reported that the levels of CD44 and HA differ between the two types of epidermal tumours, basal (BCC) and squamous cell carcinoma (SCC), as well as between different grades of SCC.
  • METHODS: Paraffin sections from 71 BCCs, 21 in situ SCCs and 27 SCCs were immunostained for MMP-7 and -9.
  • CONCLUSIONS: Our results show that in nonmelanoma skin tumours MMP-7 and -9 are present in the tumour cells, and suggest a link between MMP-7 activity and the depletion of cell surface CD44.
  • [MeSH-major] Antigens, CD44 / analysis. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Matrix Metalloproteinase 7 / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222463.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Neoplasm Proteins; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


39. Butler ST, Fosko SW: Increased prevalence of left-sided skin cancers. J Am Acad Dermatol; 2010 Dec;63(6):1006-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased prevalence of left-sided skin cancers.
  • OBJECTIVE: We sought to determine whether there is a higher frequency of skin cancer development on the left side of the body than the right.
  • METHODS: The study was a retrospective review of patients with skin cancer referred to our Mohs micrographic surgery and cutaneous oncology unit in 2004.
  • RESULTS: When including all types of skin cancers and both sexes, more cancers occurred on the left (52.6%) than the right (47.4%) (P = .059), with a stronger trend in men (P = .042).
  • There were significantly more malignant melanoma in situ on the left (31/42, 74%) than the right (11/42, 26%) (P = .002).
  • CONCLUSIONS: There were significantly more skin cancers on the left than the right side in men.
  • This discrepancy was even more profound in malignant melanoma in situ.
  • [MeSH-major] Carcinoma in Situ / epidemiology. Melanoma / epidemiology. Skin Aging / pathology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Automobile Driving / statistics & numerical data. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Environmental Exposure / statistics & numerical data. Female. Humans. Male. Middle Aged. Prevalence. Retrospective Studies. Sex Distribution. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Aging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • [CommentIn] J Am Acad Dermatol. 2011 Jul;65(1):206-7; author reply 208-10 [21679817.001]
  • [CommentIn] J Am Acad Dermatol. 2011 Jan;64(1):193-5; author reply 195-6 [21167412.001]
  • [CommentIn] J Am Acad Dermatol. 2011 Jul;65(1):207-8; author reply 208-10 [21679818.001]
  • (PMID = 20226568.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Sakiz D, Turkmenoglu TT, Kabukcuoglu F: The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. Pathol Res Pract; 2009;205(9):589-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin.
  • p53 is a well-known tumor suppressor gene, and its mutation is a common event in intraepidermal and invasive neoplasms of the skin. p63 is a homologue of the tumor suppressor gene p53, which is expressed in human basal squamous epithelium, and despite its homology to p53, it is considered to act as an oncogene.
  • We evaluated p63 and p53 expression in usual skin cancers, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), keratoacanthoma (KA), and intraepidermal neoplasms, including Bowen's disease (BD), actinic keratosis (AK), malignant melanoma in situ (MM in situ), and Paget's disease (PD) to clarify the putative role of p63 and p53 in the development and differential diagnosis of these lesions.
  • Seventeen SCC, 23 BCC, 16 KA, 26 AK, 22 BD, 7 MM in situ, and 6 PD were included in this study.
  • None of the MM in situ and PD was positive for p63.
  • The mean p53 staining was highest in BD, followed by AK, SCC, PD, KA, BCC, and normal skin.
  • Based on our findings, analysis of p63 expression may be helpful in the differential diagnosis of BD and AK versus MM in situ and PD, particularly in small biopsies.
  • [MeSH-major] Keratoacanthoma / pathology. Skin Diseases / pathology. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratosis, Actinic / metabolism. Keratosis, Actinic / pathology. Melanoma / metabolism. Melanoma / pathology. Membrane Proteins. Paget Disease, Extramammary / metabolism. Paget Disease, Extramammary / pathology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577853.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


41. Jung GW, Metelitsa AI, Dover DC, Salopek TG: Trends in incidence of nonmelanoma skin cancers in Alberta, Canada, 1988-2007. Br J Dermatol; 2010 Jul;163(1):146-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence of nonmelanoma skin cancers in Alberta, Canada, 1988-2007.
  • BACKGROUND: Nonmelanoma skin cancer (NMSC) is the most common malignancy affecting caucasian populations and has been seeing global increases in incidence for decades.
  • RESULTS: From 1988 to 2007, there were 66 192 basal cell carcinomas, 19 959 invasive squamous cell carcinomas (SCC) and 12 494 in situ SCC.
  • In situ and invasive SCC also showed a trend towards stabilization in 2000 (APC 0.36, P = 0.77) and 1995 (APC 0.01, P = 0.98), respectively.
  • As 95-99% of NMSC occurs in patients aged 40 years or older, and with its increased frequency in traditionally clothed areas, the authors recommend regular complete skin examinations starting at 40 years of age.
  • [MeSH-major] Carcinoma in Situ / epidemiology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645981.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Moubayed N, Weichenthal M, Harder J, Wandel E, Sticherling M, Gläser R: Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours. J Cancer Res Clin Oncol; 2007 Apr;133(4):253-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours.
  • As psoriasin was found to be overexpressed in human breast and bladder cancer suggesting a role in tumour progression, we investigated the expression of psoriasin in human epithelial skin tumours.
  • METHODS: Realtime reverse transcription-polymerase chain reaction experiments were performed to analyse the mRNA-expression levels of psoriasin together with involucrin as a marker for epithelial differentiation and interleukin-8 (IL-8) as a marker for inflammation in skin biopsy samples from patients with precancerous skin lesions (PSL, n = 6), squamous cell carcinoma (SCC, n = 11), basal cell carcinoma (BCC, n = 17), and healthy controls (n = 10).
  • RESULTS: Unexpectedly, mRNA expression levels for Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) revealed a variation of up to 600-fold in all cDNA-samples under investigation, indicating that GAPDH is not suitable as a housekeeping gene in human skin samples.
  • In situ hybridisation and immunohistochemical examinations identified psoriasin mRNA and protein expression in the differentiated layers of the epidermis.
  • CONCLUSION: Similar to the findings in breast and bladder cancer, the up-regulation of psoriasin might play a role in the progression of skin cancer.
  • The expression of psoriasin in human skin tumours seems to be independent from differentiation and inflammation.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Calcium-Binding Proteins / metabolism. Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Precancerous Conditions / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Gene Expression Regulation, Neoplastic. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Interleukin-8 / metabolism. Male. Middle Aged. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Reverse Transcriptase Polymerase Chain Reaction. S100 Proteins. Up-Regulation

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1983 Jul;81(1 Suppl):100s-3s [6345687.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2057-66 [10595935.001]
  • [Cites] Acta Derm Venereol. 1996 May;76(3):210-3 [8800301.001]
  • [Cites] Br J Dermatol. 2006 May;154 Suppl 1:5-7 [16712709.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):362-75 [12651909.001]
  • [Cites] Nat Immunol. 2005 Jan;6(1):57-64 [15568027.001]
  • [Cites] J Invest Dermatol. 2004 Jul;123(1):23-33 [15191538.001]
  • [Cites] Acta Derm Venereol. 2000 Jan-Feb;80(1):2-3 [10721821.001]
  • [Cites] BMC Dermatol. 2003 Feb 24;3:1 [12600274.001]
  • [Cites] Clin Exp Dermatol. 2001 Jan;26(1):72-8 [11260184.001]
  • [Cites] J Invest Dermatol. 1991 Oct;97(4):701-12 [1940442.001]
  • [Cites] Neuro Endocrinol Lett. 2002 Jul;23 Suppl 2:48-51 [12163848.001]
  • [Cites] J Urol. 1996 Jun;155(6):2105-12 [8618345.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1473-81 [16273201.001]
  • [Cites] Arch Dermatol Res. 1996 Jul;288(8):426-30 [8844119.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] BMC Cancer. 2002 Nov 06;2:28 [12421467.001]
  • [Cites] J Invest Dermatol. 1994 Sep;103(3):370-5 [8077703.001]
  • [Cites] Photochem Photobiol. 2000 Sep;72(3):374-82 [10989609.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33(9):608-13 [16965334.001]
  • [Cites] J Invest Dermatol. 1996 Jul;107(1):5-10 [8752830.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1657-67 [15905207.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1954-61 [12702588.001]
  • [Cites] Am J Pathol. 1991 Oct;139(4):869-76 [1681733.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4606-9 [8840971.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11326-34 [16357139.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):43-7 [11782356.001]
  • (PMID = 17136347.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Interleukin-8; 0 / RNA, Neoplasm; 0 / S100 Proteins; 0 / S100A7 protein, human; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


43. Li P, Gao XH, Chen HD, Zhang Y, Wang Y, Wang H, Wang Y, Xie Y: Localization of haptoglobin in normal human skin and some skin diseases. Int J Dermatol; 2005 Apr;44(4):280-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of haptoglobin in normal human skin and some skin diseases.
  • The synthesis of Hp in skin cells has not been well studied.
  • METHODS: We examined Hp expression at mRNA and protein levels by in situ hybridization and immunohistochemistry, respectively, in normal human skin and in the skin of patients with psoriasis, lichen planus, erythroderma, seborrheic keratosis, verruca vulgaris, basal cell carcinoma, systemic lupus erythematosus, pemphigus and bullous pemphigoid. RESULTS:.
  • (1) Haptoglobin mRNA was expressed in the epidermal keratinocytes (KCs), the epithelial cells of hair follicles, sebaceous glands and eccrine glands in normal skin and all dermatoses investigated. (2) Whereas compared with normal skin, the Hp mRNA in KCs of patients with psoriasis, lichen planus, erythroderma, seborrhoea keratosis and verruca vulgaris was significantly intensified, it was weaker in patients with systemic lupus erythematosus, pemphigus and bullous pemphigoid. (3) Haptoglobin protein only stained positively in some KCs of patients with psoriasis, lichen planus and erythroderma. (4) Although some but not all epidermal LCs were positively stained with anti-Hp antibody in normal skin and in skin samples from all patients, the ratios of Hp-positive LCs/total LCs were significantly higher in those diseases with intensified Hp mRNA in KCs.
  • CONCLUSIONS: Skin is another extrahepatic organ where Hp can be synthesized by KCs.
  • The expression of Hp mRNA in KCs and the Hp protein in both LCs and KCs appears to be correlated with the amount of inflammation, which might indicate that skin itself is involved in down-regulating the local inflammatory reaction by KC-synthesized Hp.
  • [MeSH-major] Haptoglobins / biosynthesis. Skin / metabolism. Skin Diseases / metabolism

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15811077.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Haptoglobins
  •  go-up   go-down


44. Brasanac D, Boricic I, Todorovic V, Tomanovic N, Radojevic S: Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin. Br J Dermatol; 2005 Dec;153(6):1166-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
  • BACKGROUND: Actinic keratosis (AK) has been defined as a precancerous lesion or an early phase in the evolution of squamous cell carcinoma (SCC) and histological changes seen in the individual cells of an AK are indistinguishable from those seen in SCC, which invade the dermis.
  • Cyclin A is an increasingly utilized proliferation marker that has functions in both S phase (DNA replication) and initiation of mitosis, whereas alterations of beta-catenin, the molecule involved in cell-cell adhesion and in signalling transduction, could promote invasive and proliferative capacities of malignant tumours.
  • OBJECTIVES: To determine cyclin A and beta-catenin expression pattern in cutaneous SCC and in in situ lesions classified as keratinocytic intraepidermal neoplasia (KIN) and, using traditional terms, as AK and Bowen's disease (BD), and to analyse it in relation to SCC differentiation, diameter and thickness.
  • Aberrant beta-catenin cellular localization demonstrated 28 lesions (25.5%), most often in the basal or peripheral parts and in the lesions with diffuse beta-catenin loss (P = 0.009), but revealed no correlation with the histological type, SCC level of differentiation or KIN grades.
  • CONCLUSIONS: Cyclin A LI showed greater difference between AK and BD than between BD and SCC, suggesting that increased proliferation (measured by cyclin A LI) characterizes progression of in situ lesions from AK to BD, whereas reduced beta-catenin expression separates more clearly SCC from the in situ lesions.
  • KIN classification does not seem to be supported by our findings, except when KIN1 and KIN2 lesions (in situ, partial thickness) are grouped.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cyclin A / metabolism. Keratosis / metabolism. Skin Neoplasms / metabolism. beta Catenin / metabolism


45. Perrem K, Lynch A, Conneely M, Wahlberg H, Murphy G, Leader M, Kay E: The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths. Hum Pathol; 2007 Feb;38(2):351-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths.
  • The incidence and aggressiveness of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma (SCC), in immunocompromised renal transplant recipients (RTRs) is dramatically higher (up to 100-fold) compared with the normal population.
  • SCC lesions are also predominant in RTRs, in contrast to the normal population where basal cell carcinoma is more common.
  • The mechanisms underlying this phenomenon are unknown, but effective treatments for these skin tumors would have a significant impact upon morbidity in this group of patients.
  • The fundamental role of telomeres and telomerase in the development of most human cancers, including melanoma, is well established, but very few reports have assessed their function during the onset of nonmelanoma skin cancer.
  • To assess whether telomere maintenance plays any role in the increased incidence of SCC in renal transplant patients, we analyzed both the telomere lengths and telomerase expression levels in 44 SCCs and 22 Bowen's disease (BD) samples (carcinoma in situ) from RTRs and nontransplant patients.
  • [MeSH-major] Bowen's Disease / etiology. Carcinoma, Squamous Cell / etiology. Kidney Transplantation / adverse effects. Skin Neoplasms / etiology. Telomere / genetics
  • [MeSH-minor] Base Sequence. Cell Line. HeLa Cells. Humans. Immunocompromised Host. Immunohistochemistry. In Situ Hybridization, Fluorescence / methods. Telomerase / biosynthesis


46. Chow KC, Lu MP, Wu MT: Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma. J Dermatol Sci; 2006 Mar;41(3):205-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma.
  • Previous clinical studies have demonstrated the over-expression of DDH in various types of cancers, including cutaneous squamous cell carcinoma (SCC), and its correlation with tumor progression and grave prognosis.
  • METHODS: DDH expression in SCC A431 cell line was examined by quantitative real-time PCR and immunoblotting.
  • RESULTS: DDH was found highly expressed by SCC A431 cells, which was barely detectable in other normal or malignant cutaneous cells, including keratinocytes, fibroblast, and basal cell carcinoma cell line.
  • [MeSH-major] Apoptosis. Carcinoma, Squamous Cell / drug therapy. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Oxidoreductases / biosynthesis
  • [MeSH-minor] Bleomycin / pharmacology. Caspase 3. Caspases / metabolism. Cell Line. Cell Line, Tumor. Disease Progression. Fibroblasts / metabolism. Humans. In Situ Nick-End Labeling. Keratinocytes / metabolism. Models, Statistical. Polycyclic Hydrocarbons, Aromatic / metabolism. Prognosis. RNA Interference. Skin Neoplasms / drug therapy. Skin Neoplasms / enzymology. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Ultraviolet Rays. Up-Regulation

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16361083.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Polycyclic Hydrocarbons, Aromatic; 0 / Tetrazolium Salts; 0 / Thiazoles; 11056-06-7 / Bleomycin; 298-93-1 / thiazolyl blue; EC 1.- / Oxidoreductases; EC 1.3.1.20 / trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


47. Paoli J, Smedh M, Wennberg AM, Ericson MB: Multiphoton laser scanning microscopy on non-melanoma skin cancer: morphologic features for future non-invasive diagnostics. J Invest Dermatol; 2008 May;128(5):1248-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiphoton laser scanning microscopy on non-melanoma skin cancer: morphologic features for future non-invasive diagnostics.
  • This study describes the morphologic features of human non-melanoma skin cancer obtained using multiphoton laser scanning microscopy (MPLSM) on freshly excised specimens from 14 patients.
  • Traditional histopathological criteria such as bowenoid dysplasia, multinucleated cells, or hyperkeratosis in squamous cell carcinoma in situ (SCCIS) (five specimens), and peripheral palisading of tumor cells in superficial basal cell carcinoma (SBCC) (six specimens) were clearly discerned.
  • The morphologic features differed significantly between these lesions and perilesional skin.
  • However, characteristic tumor aggregates were found in only one of the three investigated nodular basal cell carcinomas (NBCCs) due to limited imaging depth.
  • In addition, speckled perinuclear fluorescence was observed in both lesions and normal perilesional skin.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Microscopy, Fluorescence, Multiphoton / methods. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy. Carcinoma in Situ / pathology. Dermis / pathology. Epidermis / pathology. Follow-Up Studies. Humans. Lasers

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17989735.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Panelos J, Tarantini F, Paglierani M, Di Serio C, Maio V, Pellerito S, Pimpinelli N, Santucci M, Massi D: Photoexposition discriminates Notch 1 expression in human cutaneous squamous cell carcinoma. Mod Pathol; 2008 Mar;21(3):316-25
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoexposition discriminates Notch 1 expression in human cutaneous squamous cell carcinoma.
  • In skin cancer, Notch 1 expression is downregulated, thus supporting the hypothesis of an oncosuppressive role in cutaneous carcinomas.
  • However, as members of the Notch family undergo downregulation upon exposure to UV irradiation, we wondered whether Notch 1 expression in skin carcinomas may be governed by additional factors, including UV exposure.
  • We investigated the expression of Notch 1 and its ligands, Jagged 1, Jagged 2 and Delta-like 1, by immunohistochemistry in a series of premalignant and invasive cutaneous carcinomas, including 4 solar keratoses, 5 Bowen's disease, 5 squamous cell carcinomas on sun-exposed skin, 6 squamous cell carcinomas on sun-protected genital skin and 14 basal cell carcinomas of different histotypes (nodular, superficial type, sclerodermiform/infiltrating and baso-squamous).
  • Expression of Notch 1 was decreased in solar keratoses and invasive squamous cell carcinomas localized on sun-exposed skin.
  • In contrast, marked Notch 1 staining was observed in extragenital Bowen's disease as well as in genital (penile) human papilloma virus-related in situ and invasive squamous cell carcinomas.
  • A diffuse Notch 1 staining was detected in nodular and superficial basal cell carcinomas while sclerodermiform/infiltrating and baso-squamous basal cell carcinomas showed a low to absent Notch 1 expression.
  • Present findings show divergent expression of Notch 1 in skin cancer, depending on anatomical site and tumor histotype.
  • Thus, whereas in UV-related squamous cell photocarcinogenesis Notch 1 downregulation could mirror a tumor suppressor function of the receptor, in sun-protected squamous cell carcinomas Notch 1 was upregulated.
  • Furthermore, Notch 1 expression was minimal in basal cell carcinoma subtypes correlated with risk of recurrence (sclerodermiform/infiltrating and baso-squamous) in comparison with nodular and superficial types.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Gene Expression Regulation, Neoplastic / radiation effects. Precancerous Conditions / genetics. Receptor, Notch1 / genetics. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18192969.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


49. Rieger KE, Linos E, Egbert BM, Swetter SM: Recurrence rates associated with incompletely excised low-risk nonmelanoma skin cancer. J Cutan Pathol; 2010 Jan;37(1):59-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence rates associated with incompletely excised low-risk nonmelanoma skin cancer.
  • BACKGROUND: Reported recurrence rates for transected nonmelanoma skin cancer (NMSC) vary widely, and few studies have addressed recurrence of tumors followed clinically or treated with nonsurgical modalities.
  • METHODS: Retrospective review of dermatopathology records from January 1999 to January 2005 was conducted to identify biopsies or excision specimens with histologically transected basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) which were not subsequently excised.
  • RESULTS: Of 376 transected NMSCs, 27 (7.2%) recurred, including 20 (9%) of 223 BCCs and 7 (4.6%) SCCs in situ of 153 SCCs.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Recurrence, Local / diagnosis. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 19615009.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


50. Lipozencić J, Jurakić-Toncić R, Rados J, Celić D: Epidemiology of nonmelanoma and melanoma skin cancer in Zagreb, Croatia. Acta Dermatovenerol Croat; 2008;16(4):193-203
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of nonmelanoma and melanoma skin cancer in Zagreb, Croatia.
  • The purpose of this retrospective and hospital-based study was to evaluate the epidemiology of nonmelanoma and melanoma skin cancer at University Department of Dermatology and Venereology, Zagreb University Hospital Center and School of Medicine during the 2003-2006 period.
  • The study yielded population based results on 2911 cases of skin tumors in 2402 patients out of 16938 biopsies performed at Laboratory of Dermatologic Histopathology, University Department of Dermatology and Venereology, Zagreb University Hospital Center nd School of Medicine during the study period.
  • All newly diagnosed invasive and in situ skin cancers were recorded by use of the histopathology record forms.
  • Basal cell carcinoma was most commonly identified in the histopathology material (n=2002), followed by squamous cell carcinoma (n=533), melanoma (n=46) and cutaneous lymphoma (n=35).
  • Study results showed skin tumors to be mostly diagnosed in elderly population (median age, 71 years).
  • As expected, skin tumors were mostly found in sun-exposed areas with some specific localization of individual tumor types.
  • [MeSH-major] Carcinoma / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111143.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


51. Fontaine J, Mielczarek S, Meaume S, Senet P: [Incidence of undiagnosed skin cancers in a geriatric hospital]. Ann Dermatol Venereol; 2008 Oct;135(10):651-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence of undiagnosed skin cancers in a geriatric hospital].
  • BACKGROUND: The incidence of non melanoma skin cancers is closely correlated with age.
  • The aim of this prospective study was to evaluate the prevalence of undiagnosed skin cancers among patients hospitalized in rehabilitation and long-term care units in a geriatric hospital.
  • Clinical data included patient age at the time of the study, gender, relevant historical information, skin phototype and description of the cutaneous lesions.
  • Skin phototype was clear for 93.5% of the patients.
  • Thirty-two out of 306 patients (10.5%) presented 42 suspicious lesions and these were diagnosed by histological examination as 16 basal-cell carcinomas, seven squamous cell-carcinomas and two in situ melanomas.
  • Skin cancers were localised on the head and neck in 80% of cases.
  • The prevalence of patients with skin cancers was 5.6% in this population.
  • CONCLUSION: The prevalence of skin cancers among patients hospitalized in geriatric hospitals justifies improved training of geriatricians regarding early recognition and dermatological assessment of cutaneous tumours.
  • [MeSH-major] Skin Neoplasms / diagnosis. Skin Neoplasms / epidemiology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / epidemiology. Cross-Sectional Studies. Female. France / epidemiology. Hospitalization. Humans. Long-Term Care. Male. Melanoma / diagnosis. Melanoma / epidemiology. Middle Aged. Prevalence. Prospective Studies. Rehabilitation Centers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Dermatol Venereol. 2008 Oct;135(10):641-3 [18929911.001]
  • (PMID = 18929913.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


52. O'Grady A, Dunne C, O'Kelly P, Murphy GM, Leader M, Kay E: Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression. Histopathology; 2007 Dec;51(6):793-804
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
  • AIMS: To investigate the expression of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer (NMSC) and to compare their expression between different tumour types and with clinicopathological factors.
  • METHODS AND RESULTS: A study of 11 normal skin, 29 Bowen's disease (BD), 40 squamous cell carcinoma (SCC) and 38 basal cell carcinoma (BCC) samples for MMP-2, MMP-9, TIMP-1 and TIMP-2 expression was carried out using immunohistochemistry and in situ hybridization.
  • The expression of all metalloproteinases was greater in tumours than in normal skin.
  • CONCLUSIONS: MMP-2, MMP-9, TIMP-1 and TIMP-2 play an important role in the pathogenesis of non-melanoma skin cancer, but differ significantly in their expression levels between the tumour types examined.
  • [MeSH-major] Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 9 / biosynthesis. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-2 / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Bowen's Disease / metabolism. Bowen's Disease / pathology. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Disease Progression. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18042068.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


53. Anderegg U, Breitschwerdt K, Köhler MJ, Sticherling M, Haustein UF, Simon JC, Saalbach A: MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines. Exp Dermatol; 2005 Sep;14(9):709-18
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines.
  • Tumor-stroma interactions play a decisive role in the growth and metastasis of solid tumors, and involve signalling either by soluble mediators or direct cell-cell interaction.
  • Here, we report the isolation and characterisation of a novel cDNA (MEL4B3), which is induced in cultured dermal fibroblasts exposed to supernatants of melanoma cell lines.
  • In situ hybridisation revealed the expression of MEL4B3 in malignant melanoma increasing with tumor depth; in basal cell carcinoma and in squamous cell carcinoma.
  • MEL4B3 was barely detectable in normal skin or non-malignant melanocytic naevi.
  • Furthermore, MEL4B3 was expressed at high level in the epidermis of psoriatic skin.
  • In vitro, the expression of MEL4B3 was found to be induced by the exposure of human dermal fibroblasts to melanoma cell culture supernatants or to transforming growth factor-beta, interleukin-1 and tumor necrosis factor-alpha.
  • The expression MEL4B3 therefore reflects closely cell activation occurring during tumor growth, metastasis and inflammation.
  • [MeSH-major] Neoplasm Proteins / biosynthesis. RNA, Messenger / metabolism. Skin Neoplasms / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Blotting, Northern. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Cells, Cultured. Culture Media / metabolism. Culture Media / pharmacology. Culture Media, Conditioned / pharmacology. Cytokines / metabolism. DNA, Complementary / metabolism. Fibroblasts / metabolism. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization. Inflammation. Keratinocytes / metabolism. Microcirculation. Molecular Sequence Data. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Complementary / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098131.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Culture Media; 0 / Culture Media, Conditioned; 0 / Cytokines; 0 / DNA, Complementary; 0 / FNDC1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Complementary; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta
  •  go-up   go-down


54. Woodmansee C, Pillow J, Skinner RB Jr: The role of topical immune response modifiers in skin cancer. Drugs; 2006;66(13):1657-64
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of topical immune response modifiers in skin cancer.
  • It involves the stimulation of innate and cell-mediated immune responses through Toll-like receptor-mediated induction of cytokines.
  • Imiquimod is approved for the treatment of actinic keratoses, superficial basal cell carcinomas and warts; it has also been documented to successfully treat other forms of skin cancer such as squamous cell carcinoma in situ, melanoma and extramammary Paget's disease.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2004 May;122(5):1266-76 [15140231.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:59-61 [14616354.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Dec;47(12):3846-52 [14638493.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10 ):1027-34 [12974699.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:66-70 [14616356.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4):497-501 [12271290.001]
  • [Cites] Dermatol Surg. 2004 Aug;30(8):1101-12 [15274700.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):510-4 [15837872.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S229-35 [12271284.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4):571-7 [12271303.001]
  • [Cites] J Am Acad Dermatol. 2000 Sep;43(3):555-6 [10954675.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):945-7 [12873904.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1498-502 [12437457.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Dermatol Surg. 2005 Jun;31(6):659-64 [15996416.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):561-4 [11442593.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] J Drugs Dermatol. 2003 Jan;2(1):73-6 [12852386.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S225-8 [12271283.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):273-6 [12622616.001]
  • [Cites] Arch Dermatol. 2001 Jan;137(1):14-6 [11176654.001]
  • [Cites] Arch Dermatol. 2004 Dec;140(12 ):1542 [15611446.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49 [12902443.001]
  • [Cites] Br J Dermatol. 2001 Dec;145(6):1022-3 [11899127.001]
  • [Cites] J Am Acad Dermatol. 2002 Apr;46(4):545-8 [11907505.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):843-5 [11069469.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • (PMID = 16978032.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Imidazoles; 0 / Toll-Like Receptors; P1QW714R7M / imiquimod; V3DMU7PVXF / resiquimod
  • [Number-of-references] 35
  •  go-up   go-down


55. Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, Breuer J, Majewski S, Pfister H, Wieland U: Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol; 2005 Jul;125(1):93-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers.
  • Recent studies suggest a role of cutaneous human papillomaviruses (HPV) in non-melanoma skin cancer (NMSC) development.
  • In this study viral DNA loads of six frequent HPV types were determined by quantitative, type-specific real-time-PCR (Q-PCR) in actinic keratoses (AK, n=26), NMSC (n=31), perilesional tissue (n=22), and metastases of squamous cell carcinomas (SCC) (n=8) which were previously shown to be positive for HPV5, 8, 15, 20, 24, or 36.
  • HPV-DNA loads in AK, (partially microdissected) NMSC, and perilesional skin ranged between one HPV-DNA copy per 0.02 and 14,200 cell equivalents (median: 1 HPV-DNA copy per 344 cell equivalents; n=48).
  • In 32 of the 79 HPV-positive skin biopsies and in seven of the eight metastases viral loads were even below the detection limit of Q-PCR.
  • Low viral loads in NMSC were confirmed by in situ-hybridization showing only a few HPV-DNA-positive nuclei per section.
  • Viral loads in SCC, basal cell carcinomas, and perilesional tissue were similar.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. DNA Probes, HPV. DNA, Viral / analysis. Keratosis / virology. Papillomaviridae / isolation & purification. Skin Neoplasms / virology. Viral Load

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Invest Dermatol. 2005 Jul;125(1):xii-xiii [15982294.001]
  • (PMID = 15982308.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral
  •  go-up   go-down


56. Utikal J, Udart M, Leiter U, Kaskel P, Peter RU, Krähn G: Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer. Cancer Lett; 2005 Mar 10;219(2):197-204
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer.
  • Deregulation of the cell-cycle G1-restriction point control via abnormalities of Rb-pathway components is a frequent event in the formation of cancer.
  • The aim of this study was to evaluate numerical aberrations of the Cyclin D1 (CCND1, PRAD1, bcl-1) gene locus at chromosome 11q13 in basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) of the skin and to compare it with the Cyclin D1 protein expression.
  • Fluorescence in situ hybridization with DNA-probes specific for the Cyclin D1 gene locus and the centromere of chromosome 11 as well as immunostaining for Cyclin D1 protein was applied on 5 microm serial paraffin sections.
  • This might result in deregulation of cell cycle control, eventually leading to uncontrolled cell cycle progression.
  • [MeSH-major] Aneuploidy. Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Chromosomes, Human, Pair 11. Cyclin D1 / genetics. Cyclin D1 / metabolism. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723720.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1
  •  go-up   go-down


57. Ashton KJ, Carless MA, Griffiths LR: Cytogenetic alterations in nonmelanoma skin cancer: a review. Genes Chromosomes Cancer; 2005 Jul;43(3):239-48
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic alterations in nonmelanoma skin cancer: a review.
  • Our purpose in this review is to discuss the cytogenetic findings on a number of nonmelanoma skin cancers, including squamous- and basal cell carcinomas, keratoacanthoma, squamous cell carcinoma in situ (Bowen's disease), and solar keratosis.
  • Through classical cytogenetic techniques, as well as fluorescence-based techniques such as fluorescence in situ hybridization and comparative genomic hybridization, numerous chromosomal alterations have been identified.
  • These aberrations may aid in further defining the stages and classifications of nonmelanoma skin cancer and also may implicate chromosomal regions involved in progression and metastatic potential.
  • This information, along with the development of newer technologies (including laser capture microdissection and comparative genomic hybridization arrays) that allow for more refined analysis, will continue to increase our knowledge about the role of chromosomal events at all stages of cancer development and progression and, more specifically, about how they are associated with nonmelanoma skin cancer.
  • [MeSH-major] Chromosome Aberrations. Mutation. Skin Neoplasms / genetics
  • [MeSH-minor] Chromosome Mapping. DNA Damage / radiation effects. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Loss of Heterozygosity. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15834942.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


58. Del Rosso JQ: The treatment of viral infections and nonmelanoma skin cancers. Cutis; 2007 Apr;79(4 Suppl):29-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of viral infections and nonmelanoma skin cancers.
  • Immunomodulatory therapy, which functions to upregulate immune response, may be directed against a variety of disease states, including viral infections and skin malignancies.
  • Topical imiquimod has been studied for a variety of different disorders including human papillomavirus infection, molluscum contagiosum, actinic keratosis (AK), squamous cell carcinoma (SCC) in situ, superficial basal cell carcinoma (sBCC), nodular basal cell carcinoma (nBCC), and lentigo maligna.
  • This article focuses on therapies designed to augment immune response to treat viral infections and nonmelanoma skin cancers and reviews clinical applications, efficacy, recommended treatment regimens, monitoring of response, and avoidance of pitfalls associated with the use of topical imiquimod.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Interferons / therapeutic use. Skin Diseases, Viral / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508493.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 9008-11-1 / Interferons; 99011-02-6 / imiquimod
  • [Number-of-references] 53
  •  go-up   go-down


59. Barysch MJ, Cozzio A, Kolm I, Hrdlicka SR, Brand C, Hunger R, Kreyden O, Schaffner R, Zaugg T, Dummer R: Internet based health promotion campaign against skin cancer - Results of www.skincheck.ch in Switzerland. Eur J Dermatol; 2010 Jan-Feb;20(1):109-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Internet based health promotion campaign against skin cancer - Results of www.skincheck.ch in Switzerland.
  • Conventional skin cancer prevention programs appeal to limited populations, and the middle aged male population responds less frequently.
  • Our objective was to establish a complementary health promotion campaign tool for skin cancer prevention.
  • Internet-based education, instruction for self assessment and teledermatological evaluation of skin lesions by an expert commission of dermatologists was used.
  • According to user's declarations, at least 8 (8.5%) malignant lesions (1 melanoma in situ, 1 squamous cell carcinoma, 4 basal cell carcinomas, 2 malignant lesions without declared diagnosis) were finally diagnosed by physicians.
  • We conclude that internet-based, interactive, educational programs, in addition to existing health promotion campaigns, can enhance public participation in the middle aged male population in skin cancer prevention.
  • [MeSH-major] Health Education. Health Promotion. Internet. Skin Neoplasms / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825529.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


60. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM: A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol; 2006 Mar;154(3):498-504
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based study of skin cancer incidence and prevalence in renal transplant recipients.
  • OBJECTIVES: To determine the incidence of all cancers following renal transplantation and to make a detailed examination of trends and patterns associated with postrenal transplant skin cancers.
  • METHODS: Integration of data from the national renal transplant database and the national cancer registry in Ireland enabled accurate determination of the number of renal transplant recipients (RTRs) with skin cancers and other malignancies in the time period 1 January 1994 to 31 December 2001.
  • RESULTS: We demonstrated a biphasic increase in skin cancer incidence following renal transplantation, determined by the age at transplantation.
  • The number of nonmelanoma skin cancers (NMSCs) registered in RTRs accounted for 1% of all NMSCs registered nationally over the study period.
  • The standardized incidence rates for invasive NMSC (33-fold increase) and in situ carcinoma of the skin (65-fold increase) were significantly increased (P < 0.05).
  • The risk for invasive squamous cell carcinoma (SCC) was increased 82-fold compared with the nontransplanted population.
  • CONCLUSIONS: This comprehensive national study illustrates how rates of skin cancer in Irish RTRs have influenced the national incidence of skin cancer.
  • The high incidence of SCC, basal cell carcinoma and Bowen's disease in the early post-transplant period for older patients and the cumulative risk in younger patients with increased duration of transplantation highlight the importance of implementing early and continued cancer surveillance regimens post-transplant.
  • [MeSH-major] Kidney Transplantation. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / immunology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / immunology. Epidemiologic Methods. Female. Humans. Immunocompromised Host. Immunosuppression / adverse effects. Ireland / epidemiology. Male. Sex Distribution

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445782.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


61. Yaroslavsky AN, Barbosa J, Neel V, DiMarzio C, Anderson RR: Combining multispectral polarized light imaging and confocal microscopy for localization of nonmelanoma skin cancer. J Biomed Opt; 2005 Jan-Feb;10(1):14011
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining multispectral polarized light imaging and confocal microscopy for localization of nonmelanoma skin cancer.
  • In practice, pathologists use microscopes at low and high power to view tumor margins and cell features, respectively.
  • Therefore, we study the combination of CM and MSPLI for demarcation of nonmelanoma skin cancers.
  • Freshly excised thick skin samples with nonmelanoma cancers are rapidly stained with either toluidine or methylene blue dyes, rinsed in acetic acid, and imaged using MSPLI and CM.
  • This combined in situ technique has potential to guide cancer surgery more rapidly and at lower cost than conventional histopathology.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Microscopy, Confocal. Microscopy, Polarization. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Society of Photo-Optical Instrumentation Engineers
  • (PMID = 15847592.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB002423-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 15XUH0X66N / Tolonium Chloride; T42P99266K / Methylene Blue
  •  go-up   go-down


62. Szeimies RM, Morton CA, Sidoroff A, Braathen LR: Photodynamic therapy for non-melanoma skin cancer. Acta Derm Venereol; 2005;85(6):483-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for non-melanoma skin cancer.
  • Photodynamic therapy is a treatment modality that has been shown to be effective mainly for the dermato-oncologic conditions: actinic keratosis, Bowen's disease, in situ squamous cell carcinoma and basal cell carcinoma.
  • For actinic keratosis and basal cell carcinoma, methyl aminolevulinate-photodynamic therapy is already approved in Europe, Australia and New Zealand, and is now also approved for actinic keratosis in the US.
  • [MeSH-major] Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Humans. Photosensitizing Agents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396794.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 51
  •  go-up   go-down


63. Henning JS, Firoz BF: Combat dermatology: the prevalence of skin disease in a deployed dermatology clinic in Iraq. J Drugs Dermatol; 2010 Mar;9(3):210-4
MedlinePlus Health Information. consumer health - Veterans and Military Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combat dermatology: the prevalence of skin disease in a deployed dermatology clinic in Iraq.
  • This paper outlines the prevalence of skin disease among deployed service men and women in Operation Iraqi Freedom.
  • Eight percent (n=205) of the total visits were for skin cancer.
  • This included: basal cell carcinoma, squamous cell carcinoma both in-situ and invasive, mycosis fungoides and melanoma.
  • CONCLUSION: This is the largest publication of the prevalence of skin disease in an exclusively dermatologic clinic in a combat setting.
  • For the first time the presence of skin cancer is noted in a combat setting.
  • [MeSH-major] Military Personnel. Skin Diseases / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Eczema / epidemiology. Female. Humans. Iraq War, 2003-2011. Male. Middle Aged. Prevalence. Skin Diseases, Infectious / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232580.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Kacerovska D, Szepe P, Vanecek T, Nemcova J, Michal M, Mukensnabl P, Kazakov DV: Spiradenocylindroma-like basaloid carcinoma of the anus and rectum: case report, including HPV studies and analysis of the CYLD gene mutations. Am J Dermatopathol; 2008 Oct;30(5):472-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spiradenocylindroma-like basaloid carcinoma of the anus and rectum: case report, including HPV studies and analysis of the CYLD gene mutations.
  • The authors report a case of basaloid carcinoma involving the anus and rectum of a 57-year-old woman.
  • Microscopically, the tumor showed unusual morphologic features strongly resembling a spiradenocylindroma because it consisted, in most parts, of basaloid cell nodules arranged in a jigsaw-puzzle fashion containing or surrounded by eosinophilic basal membrane material; in addition, there were intratumoral lymphocytes.
  • The overlying squamous epithelium manifested dysplastic changes compatible with in situ squamous carcinoma that gradually became invasive and blended with basaloid cell islands; additionally, there were koilocytes in the squamous epithelium.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Human papillomavirus 16 / pathogenicity. Rectal Neoplasms / pathology. Skin Neoplasms / pathology. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18806492.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


65. Kacerovská D, Pizinger K, Majer F, Smíd F: Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract--a pilot study. Photochem Photobiol; 2008 May-Jun;84(3):779-85
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract--a pilot study.
  • However, there is only limited knowledge regarding the photodynamic effect of hypericin on nonmelanoma skin cancer cells.
  • The aim of this prospective study was to investigate the efficacy of photodynamic therapy with topical application of an extract of H. perforatum in actinic keratosis, basal cell carcinoma (BCC) and morbus Bowen (carcinoma in situ).
  • The extract of H. perforatum was applied on the skin lesions under occlusion and that was followed by irradiation with 75 J cm(-2) of red light 2 h later.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Hypericum. Perylene / analogs & derivatives. Photochemotherapy / methods. Plant Preparations / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179625.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Preparations; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


66. Hargis AM, Baldessari AE, Walder EJ: Intraepidermal adenocarcinoma in the perianal skin of two cats, a condition resembling human extramammary Paget's disease. Vet Dermatol; 2008 Feb;19(1):31-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepidermal adenocarcinoma in the perianal skin of two cats, a condition resembling human extramammary Paget's disease.
  • This report describes two cats with lesions in perianal skin consisting of atypical intraepidermal neoplastic cells.
  • Differential diagnoses included intraepidermal adenocarcinoma, in situ squamous or basal cell carcinoma, junctional amelanotic melanoma, and epitheliotropic tumours of histiocytic or lymphocytic origin.
  • The keratinocytes and basal cells were negative for CK8/18.
  • The clinical features, histological appearance, and immunohistochemical staining of the skin lesions were consistent with those described for human perianal extramammary Paget's disease.
  • [MeSH-major] Adenocarcinoma / veterinary. Cat Diseases / diagnosis. Perineum / pathology. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177290.001).
  • [ISSN] 0959-4493
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Velazquez EF, Melamed J, Barreto JE, Aguero F, Cubilla AL: Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases. Am J Surg Pathol; 2005 Sep;29(9):1152-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases.
  • A total of 400 cases of squamous cell carcinoma of the penis were reviewed from which 15 sarcomatoid carcinomas (4%) were identified.
  • Immunohistochemical studies for expression of AE1/AE3, Cam 5.2, 34betaE12, EMA, vimentin, muscle specific actin, smooth muscle actin, desmin, S-100, p63, and p53 and in situ hybridization studies for HPV were performed in 5 cases.
  • Grossly, most tumors were large, polypoid, and ulcerated masses frequently affecting the glans (93%) and deeply invading corpora cavernosa (80%) and skin.
  • Four cases showed a minor mixed component of usual, papillary, verrucous, and basaloid carcinoma.
  • One of the cases was multicentric with a separate independent focus of well-differentiated carcinoma with pseudohyperplastic features.
  • Immunohistochemical studies and HPV in situ hybridization were done in 5 cases.
  • HPV in situ hybridization was negative in all cases.
  • Diffuse immunoreactivity for p53, compared with a more basal and focal reactivity in differentiated squamous cell carcinoma, may be indicative of a late mutation in the natural progression of the disease.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Penile Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096403.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


68. Bogner PN, Su LD, Fullen DR: Cluster designation 5 staining of normal and non-lymphoid neoplastic skin. J Cutan Pathol; 2005 Jan;32(1):50-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cluster designation 5 staining of normal and non-lymphoid neoplastic skin.
  • RESULTS: Within normal skin, CD5 labeled lymphocytes, apocrine glands, deep dermal eccrine glands, and smooth muscle (weak).
  • Microcystic adnexal carcinoma demonstrated focal staining of deeper ductal structures (71%, n=7), whereas desmoplastic trichoepithelioma and basal cell carcinoma showed only rare positive cells.
  • Pagetoid Bowen's disease (n=6), intraepidermal sebaceous carcinoma (n=3), nor melanoma in situ (n=6) showed any CD5 staining.
  • CONCLUSIONS: Immunohistochemical staining for CD5 is extremely useful in the differential diagnosis of pagetoid epidermal lesions and will mark mammary and extramammary Paget's disease, but not pagetoid Bowen's disease, melanoma in situ, or sebaceous carcinoma.
  • [MeSH-major] Antigens, CD5 / metabolism. Skin / metabolism. Skin Neoplasms / enzymology. Skin Neoplasms / metabolism. Staining and Labeling
  • [MeSH-minor] Cell Count. Diagnosis, Differential. Humans. Immunohistochemistry. Paget Disease, Extramammary / diagnosis. Paget's Disease, Mammary / diagnosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660655.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


69. Paoli J, Smedh M, Ericson MB: Multiphoton laser scanning microscopy--a novel diagnostic method for superficial skin cancers. Semin Cutan Med Surg; 2009 Sep;28(3):190-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiphoton laser scanning microscopy--a novel diagnostic method for superficial skin cancers.
  • The increasing incidence of skin cancer and the importance of early diagnosis is a challenge, which requires the development of reliable, cost-effective, noninvasive, diagnostic techniques.
  • When studying human skin, MPLSM provides high-resolution fluorescence imaging, allowing visualization of cellular and subcellular structures of the epidermis and upper dermis.
  • This review covers the application of MPLSM as a diagnostic tool for superficial skin cancers, such as basal cell carcinomas, squamous cell carcinoma in situ, and melanomas.
  • MPLSM has also been applied in other research areas related to skin, which will be mentioned briefly.
  • The morphologic features observed in MPLSM images of skin tumors are comparable to traditional histopathology.
  • Although further investigations are required to make MPLSM a mainstream clinical diagnostic tool, MPLSM has the potential of becoming a noninvasive, bedside, histopathologic technique for the diagnosis of superficial skin cancers.
  • [MeSH-major] Microscopy, Confocal / methods. Microscopy, Fluorescence, Multiphoton / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19782943.001).
  • [ISSN] 1558-0768
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


70. Vidal VP, Chaboissier MC, Lützkendorf S, Cotsarelis G, Mill P, Hui CC, Ortonne N, Ortonne JP, Schedl A: Sox9 is essential for outer root sheath differentiation and the formation of the hair stem cell compartment. Curr Biol; 2005 Aug 9;15(15):1340-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sox9 is essential for outer root sheath differentiation and the formation of the hair stem cell compartment.
  • BACKGROUND: The mammalian hair represents an unparalleled model system to understand both developmental processes and stem cell biology.
  • Functionally, the ORS has been implicated in the migration of hair stem cells from the stem cell niche toward the hair bulb.
  • However, factors required for the differentiation of this critical cell lineage remain to be identified.
  • RESULTS: Sox9 expression can be first detected in the epithelial component of the hair placode but then becomes restricted to the outer root sheath (ORS) and the hair stem cell compartment (bulge).
  • Using tissue-specific inactivation of Sox9, we demonstrate that this gene serves a crucial role in hair differentiation and that skin deleted for Sox9 lacks external hair.
  • Moreover, Sox9 knock hair show severe proliferative defects and the stem cell niche never forms.
  • Finally, we show that Sox9 expression depends on sonic hedgehog (Shh) signaling and demonstrate overexpression in skin tumors in mouse and man.
  • CONCLUSIONS: We conclude that although Sox9 is dispensable for hair induction, it directs differentiation of the ORS and is required for the formation of the hair stem cell compartment.
  • Our genetic analysis places Sox9 in a molecular cascade downstream of sonic hedgehog and suggests that this gene is involved in basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Gene Expression Regulation, Developmental. Hair Follicle / cytology. Hair Follicle / embryology. High Mobility Group Proteins / metabolism. Signal Transduction / physiology. Skin Neoplasms / metabolism. Stem Cells / cytology. Transcription Factors / metabolism
  • [MeSH-minor] Alopecia / genetics. Animals. GATA3 Transcription Factor / metabolism. Gene Silencing. Hedgehog Proteins. Immunohistochemistry. In Situ Hybridization. Mice. Mice, Transgenic. Microscopy, Electron, Scanning. SOX9 Transcription Factor. Trans-Activators / metabolism


71. Ferreira M, Fujiwara H, Morita K, Watt FM: An activating beta1 integrin mutation increases the conversion of benign to malignant skin tumors. Cancer Res; 2009 Feb 15;69(4):1334-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An activating beta1 integrin mutation increases the conversion of benign to malignant skin tumors.
  • One of these, T188Ibeta1, was identified as a heterozygous mutation in a poorly differentiated squamous cell carcinoma (SCC) and shown to activate extracellular matrix adhesion and inhibit keratinocyte differentiation in vitro.
  • To study its contribution to tumor development, we overexpressed the mutant or wild-type (WT) human beta1 subunit in the basal layer of mouse epidermis using the keratin 14 promoter.
  • The transgenic integrins were expressed at the cell surface and were functional, with the T188Ibeta1 subunit promoting cell spreading to a greater extent than WTbeta1.
  • Epidermal proliferation and differentiation were unaffected and no expansion of the stem cell compartment was detected.
  • [MeSH-major] Antigens, CD29 / genetics. Mutation. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Adhesion. Cell Differentiation. Cell Division. Female. Flow Cytometry. Heterozygote Detection. Humans. In Situ Hybridization. Keratinocytes / cytology. Keratinocytes / physiology. Mice. Mice, Transgenic. Polymerase Chain Reaction. Polymorphism, Genetic. Skin / cytology


72. Li L, Shukla S, Lee A, Garfield SH, Maloney DJ, Ambudkar SV, Yuspa SH: The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res; 2010 Jun 1;70(11):4509-19
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.
  • Ingenol-3-angelate (Ing3A), extracted from Euphorbia peplus, is currently in clinical trials for eradicating basal cell carcinoma, actinic keratosis, and squamous cell carcinoma (SCC) in situ by topical application.
  • Ing3A and PMA both induced acute neutrophilic inflammation on mouse skin, but only Ing3A caused subcutaneous hemorrhage and vascular damage.
  • Both Ing3A and PMA activated extracellular signal-regulated kinase 1/2 (ERK1/2) in epidermis, but Ing3A also activated ERK1/2 in skin dermal fibroblasts and endothelial cells.
  • [MeSH-major] Antineoplastic Agents / metabolism. Diterpenes / metabolism. P-Glycoprotein / metabolism. Skin Neoplasms / drug therapy. Skin Neoplasms / metabolism
  • [MeSH-minor] Administration, Topical. Animals. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Cell Line, Tumor. Drug Eruptions / enzymology. Drug Eruptions / etiology. Enzyme Activation / drug effects. Humans. Keratinocytes / drug effects. Keratinocytes / enzymology. Melanoma, Experimental / blood supply. Melanoma, Experimental / drug therapy. Melanoma, Experimental / metabolism. Mice. Mice, Inbred BALB C. Mice, Nude. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / metabolism. P-Glycoproteins. Protein Binding. Protein Kinase C / metabolism. Skin / drug effects. Skin / enzymology. Tetradecanoylphorbol Acetate / pharmacology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):2092-102 [17620438.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59 [17428165.001]
  • [Cites] J Invest Dermatol. 2008 Mar;128(3):643-54 [17882268.001]
  • [Cites] Cancer Immunol Immunother. 2008 Aug;57(8):1241-51 [18265980.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):743-54 [18813320.001]
  • [Cites] J Control Release. 2008 Nov 12;131(3):198-204 [18725258.001]
  • [Cites] Drug Metab Dispos. 2009 Feb;37(2):359-65 [18971320.001]
  • [Cites] Australas J Dermatol. 2009 Feb;50(1):16-22 [19178487.001]
  • [Cites] Biochim Biophys Acta. 2009 May;1794(5):860-71 [19285158.001]
  • [Cites] Facial Plast Surg Clin North Am. 2009 Aug;17(3):309-24 [19698913.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):507-18 [19636328.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1202-5 [19726764.001]
  • [Cites] J Control Release. 2010 Feb 15;141(3):277-99 [19850095.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8547-58 [10567579.001]
  • [Cites] J Invest Dermatol. 2000 Jul;115(1):19-23 [10886502.001]
  • [Cites] J Invest Dermatol. 2001 Apr;116(4):541-8 [11286621.001]
  • [Cites] J Investig Dermatol Symp Proc. 2002 Dec;7(1):17-26 [12518788.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6547-55 [14559850.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7468-85 [14576852.001]
  • [Cites] Mol Pharmacol. 2004 Mar;65(3):675-84 [14978246.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2833-9 [15087400.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3243-55 [15126366.001]
  • [Cites] Cancer Res. 1973 Mar;33(3):542-6 [4689903.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1723-5 [4762943.001]
  • [Cites] Cancer Res. 1980 Dec;40(12):4694-703 [7438101.001]
  • [Cites] Cancer Res. 1981 May;41(5):1967-72 [7214365.001]
  • [Cites] Science. 1986 May 2;232(4750):643-5 [3457471.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3174-9 [3107806.001]
  • [Cites] Carcinogenesis. 1989 Mar;10(3):531-40 [2924397.001]
  • [Cites] Carcinogenesis. 1993 Feb;14(2):205-9 [8435862.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26079-81 [8253722.001]
  • [Cites] Am J Physiol. 1994 Sep;267(3 Pt 1):L223-41 [7943249.001]
  • [Cites] J Cell Physiol. 1995 Apr;163(1):105-14 [7896886.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29995-30002 [9792720.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1651-8 [15634659.001]
  • [Cites] J Invest Dermatol. 2005 Jan;124(1):28-37 [15654950.001]
  • [Cites] J Immunol. 2005 Feb 1;174(3):1686-92 [15661932.001]
  • [Cites] Cancer Cell. 2005 May;7(5):411-23 [15894262.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1362-8 [15845901.001]
  • [Cites] Int J Pharm. 2005 Nov 23;305(1-2):2-12 [16246513.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):378-86 [16158048.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2757-66 [16964312.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):8123-32 [17114487.001]
  • [Cites] Semin Immunopathol. 2007 Apr;29(1):3-14 [17621950.001]
  • (PMID = 20460505.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC005445-24
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3-ingenyl angelate; 0 / ABCB1 protein, human; 0 / Antineoplastic Agents; 0 / Diterpenes; 0 / P-Glycoprotein; 0 / P-Glycoproteins; EC 2.7.11.13 / Protein Kinase C; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS193846; NLM/ PMC2880198
  •  go-up   go-down


73. Bongiovanni L, Colombi I, Fortunato C, Della Salda L: Survivin expression in canine epidermis and in canine and human cutaneous squamous cell carcinomas. Vet Dermatol; 2009 Oct;20(5-6):369-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in canine epidermis and in canine and human cutaneous squamous cell carcinomas.
  • Survivin, a member of the inhibitor of apoptosis protein (IAP) family, is ubiquitously expressed during tissue development, undetectable in most normal tissues, but re-expressed in most cancers, including skin malignancies.
  • Expression of survivin was evaluated retrospectively in 19 canine cutaneous squamous cell carcinomas (SCCs; one in situ; 16 well differentiated; one invasive, one lymph node metastasis) and 19 well differentiated SCCs from human beings.
  • Seven specimens of normal canine skin were included.
  • Scattered survivin positive nuclei were identified in the epidermal basal cell layer of normal canine skin.
  • Nuclear survivin expression was identified in 18 of 19 human and in all canine SCCs, mainly along the base of the tumour cell population.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cysteine Proteinase Inhibitors / metabolism. Gene Expression Regulation, Neoplastic / physiology. Microtubule-Associated Proteins / metabolism
  • [MeSH-minor] Animals. Dog Diseases / metabolism. Dogs. Humans. Inhibitor of Apoptosis Proteins. Mitosis. Retrospective Studies. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178473.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Cysteine Proteinase Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


74. Nieuwenhuis E, Barnfield PC, Makino S, Hui CC: Epidermal hyperplasia and expansion of the interfollicular stem cell compartment in mutant mice with a C-terminal truncation of Patched1. Dev Biol; 2007 Aug 15;308(2):547-60
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal hyperplasia and expansion of the interfollicular stem cell compartment in mutant mice with a C-terminal truncation of Patched1.
  • PTCH1 mutations in humans are found in basal cell carcinoma (BCC) and irradiated Ptc1(+/-) mice recapitulate this phenotype.
  • However, due to embryonic lethality associated with the Ptc1 null mutation, its normal function in embryonic and adult skin remains unknown.
  • Postnatal Ptc1(mes/mes) skin displays severe basal cell layer hyperplasia and increased proliferation, while stratification of the suprabasal layers is mostly normal.
  • Interestingly, truncation of the Ptc1 CTD did not result in skin tumors.
  • However, long term labeling studies revealed a greater than three-fold increase in label-retaining cells in the interfollicular epidermis of Ptc1(mes/mes) adults, indicating possible expansion of the epidermal stem cell compartment.
  • Increased expression of regulators of epidermal homeostasis, c-Myc and p63, was also observed in Ptc1(mes/mes) adult skin.
  • These results suggest that the CTD of Ptc1 is involved in regulating epidermal homeostasis in mature skin.
  • [MeSH-major] Receptors, Cell Surface / genetics. Skin Abnormalities / genetics. Skin Abnormalities / pathology. Stem Cells / pathology
  • [MeSH-minor] Animals. Base Sequence. Cell Proliferation. DNA Primers / genetics. Gene Expression Regulation, Developmental. Genes, myc. Hedgehog Proteins / metabolism. Homeostasis. Humans. Hyperplasia. In Situ Hybridization. Mice. Mice, Mutant Strains. Phenotype. Sequence Deletion. Signal Transduction. Skin / cytology. Skin / embryology. Skin / growth & development. Skin / metabolism


75. Martinsson H, Yhr M, Enerbäck C: Expression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiation. Exp Dermatol; 2005 Mar;14(3):161-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S100A7 and S100A9 have been shown to be markedly upregulated both in ductal carcinoma in situ of the breast and in psoriasis.
  • They were both absent in undifferentiated basalioma and strongly expressed in carcinoma in situ, as well as in keratoacanthoma and differentiated squamous cell carcinoma.
  • In normal epithelium, they were expressed in the superficial, differentiated region of the epithelium rather than in the basal region.
  • [MeSH-minor] Blotting, Western. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation / physiology. Cell Line. Computer Systems. Humans. Immunohistochemistry. Keratoacanthoma / metabolism. Keratoacanthoma / pathology. Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction. S100 Proteins. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15740587.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Calgranulin B; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


76. Babilas P, Landthaler M, Szeimies RM: Photodynamic therapy in dermatology. Eur J Dermatol; 2006 Jul-Aug;16(4):340-8
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, topical photodynamic therapy (PDT) has received approval for the treatment of dermato-oncologic conditions like actinic keratoses, Bowen's disease, in-situ squamous cell carcinoma and basal cell carcinoma in many countries all over the world.
  • Due to the easy accessibility of skin to light activation, incoherent lamps or LED arrays are suitable for PDT.
  • Either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving inflammatory skin conditions are induced.
  • Treating superficial non-melanoma skin cancer, PDT has been shown to be highly efficient despite the low level of invasiveness.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Basal Cell / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935788.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 80
  •  go-up   go-down


77. Wolf IH, Kodama K, Cerroni L, Kerl H: Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol; 2007 Jun;29(3):237-41
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical imiquimod (IQ) is an effective treatment for genital warts and various malignant tumors of the skin.
  • We investigated the composition of the inflammatory cell infiltrate before, during, and after the treatment of 10 superficial cutaneous malignancies (melanoma in situ (n = 4), melanoma metastasis (n = 1), squamous cell carcinoma in situ (n = 4), and basal cell carcinoma (n = 1) with 5% IQ cream.
  • These findings further support previous investigations that the antitumor effects of IQ result from an enhanced cytotoxic T-cell mediated immune response and from the recruitment of plasmacytoid dendritic cells to the skin.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Inflammation / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Bowen's Disease / chemistry. Bowen's Disease / drug therapy. Bowen's Disease / pathology. Carcinoma in Situ / chemistry. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Female. Humans. Hutchinson's Melanotic Freckle / chemistry. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / pathology. Keratosis / drug therapy. Keratosis / metabolism. Keratosis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519620.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Biomarkers, Tumor; 99011-02-6 / imiquimod
  •  go-up   go-down


78. Babilas P, Szeimies RM: The use of photodynamic therapy in dermatology. G Ital Dermatol Venereol; 2010 Oct;145(5):613-30
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In dermatology, topical photodynamic therapy (PDT) is a well established treatment modality which has mainly shown to be effective for dermato-oncologic conditions like actinic keratosis, Bowen's disease, in-situ squamous cell carcinoma and superficial basal cell carcinoma.
  • However, a therapeutical benefit of PDT is also evident for inflammatory dermatoses like localized scleroderma, acne vulgaris and granuloma annulare as well as for aesthetic indications like photo aged skin or sebaceous gland hyperplasia.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Carcinoma, Basal Cell / drug therapy. Cosmetic Techniques. Humans. Keratosis, Actinic / drug therapy. Light. Photosensitizing Agents / therapeutic use. Psoriasis / drug therapy. Skin Neoplasms / drug therapy. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930696.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


79. Ozkağnici A, Acar H, Zengin N, Okudan S: Evaluation of aneuploidy frequency for chromosomes 6 and 17 in eyelid tumours using the FISH technique. Cell Biol Int; 2007 Mar;31(3):215-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are very common skin tumours, the incidence of chromosome aneuploidy with regard to the eyelid has not been investigated.
  • We aimed to find the frequency of chromosome 6 and 17 aneuploidies in eyelid tumours' interphase nuclei with fluorescence in situ hybridization (I-FISH) with chromosome specific DNA probes.
  • Distribution of hybridization signals for chromosome 6 and 17 was wide ranging, indicating heterogeneity of cell populations with aneuploidy between patients.
  • [MeSH-major] Aneuploidy. Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Chromosome Aberrations / statistics & numerical data. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 6. Eyelid Neoplasms / genetics
  • [MeSH-minor] Aged. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Skin Neoplasms / genetics. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164085.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


80. Moore AY: Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J Dermatolog Treat; 2009;20(6):328-35
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the indications for 5-FU approved by the US Food and Drug Administration include actinic keratosis and superficial basal cell carcinoma, studies also have demonstrated therapeutic efficacy for 5-FU in the treatment of many other dermatological conditions, including squamous cell carcinoma in situ, warts, psoriasis of the nail, keratoacanthoma, and vitiligo.
  • [MeSH-major] Dermatologic Agents / therapeutic use. Fluorouracil / therapeutic use. Skin Diseases / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Clinical Trials as Topic. Humans. Keratoacanthoma / drug therapy. Keratosis, Actinic / drug therapy. Nail Diseases / drug therapy. Psoriasis / drug therapy. Randomized Controlled Trials as Topic. Skin Neoplasms / drug therapy. Treatment Outcome. Vitiligo / drug therapy. Warts / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954388.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dermatologic Agents; U3P01618RT / Fluorouracil
  • [Number-of-references] 50
  •  go-up   go-down


81. Sellheyer K, Krahl D: Ber-EP4 enhances the differential diagnostic accuracy of cytokeratin 7 in pagetoid cutaneous neoplasms. J Cutan Pathol; 2008 Apr;35(4):366-72
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, cases of cytokeratin 7-positive pagetoid squamous cell carcinoma in situ are reported in the literature.
  • The monoclonal antibody Ber-EP4 is diagnostically highly reliable in the differentiation between basal cell carcinoma and cutaneous squamous cell carcinoma.
  • METHODS: Biopsy samples from 21 cases of extramammary Paget's disease, 12 pagetoid squamous cell carcinomas in situ and 10 pagetoid melanomas in situ of the superficial spreading type were examined immunohistochemically with Ber-EP4, 34betaE12 and HMB-45.
  • CONCLUSIONS: Ber-EP4 reliably differentiates extramammary Paget's disease from pagetoid squamous cell carcinoma in situ and pagetoid melanoma in situ.
  • The antibody should be included along with a panel of other markers when evaluating for pagetoid cutaneous neoplasms in order to avoid a possible misdiagnosis of pagetoid squamous cell carcinoma in situ.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Keratin-7 / metabolism. Melanoma / diagnosis. Paget Disease, Extramammary / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333896.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-7; 0 / human epithelial antigen-125
  •  go-up   go-down


82. Ahlgrimm-Siess V, Hofmann-Wellenhof R, Cao T, Oliviero M, Scope A, Rabinovitz HS: Reflectance confocal microscopy in the daily practice. Semin Cutan Med Surg; 2009 Sep;28(3):180-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our aim was to show the value of RCM for diagnosis and management decisions related to pigmented and nonpigmented skin neoplasms seen in daily practice.
  • Six cases of clinically and dermoscopically equivocal skin lesions, for which RCM facilitated making the correct diagnosis, are presented.
  • Three flat pigmented skin lesions with dermoscopic signs of regression showed distinct RCM features that allowed their correct classification as pigmented basal cell carcinoma, pigmented actinic keratosis, and melanoma on sun-damaged skin.
  • A flat nonpigmented skin lesion on the face, which did not show distinct clinical or dermoscopic features, was correctly diagnosed as basal cell carcinoma based on RCM findings.
  • In addition, the response of a pigmented actinic keratosis and a melanoma in situ on sun-damaged skin to noninvasive topical treatment was monitored using RCM.
  • RCM is a promising and practical imaging tool for the diagnosis and follow-up of pigmented and nonpigmented skin lesions.
  • [MeSH-major] Dermoscopy / methods. Melanoma / pathology. Neoplasms, Basal Cell / pathology. Nevus / pathology. Point-of-Care Systems. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19782942.001).
  • [ISSN] 1558-0768
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Vun Y, De'Ambrosis B, Spelman L, Muir JB, Yong-Gee S, Wagner G, Lun K: Seborrhoeic keratosis and malignancy: collision tumour or malignant transformation? Australas J Dermatol; 2006 May;47(2):106-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective study of 813 histological specimens reported as seborrhoeic keratoses included 43 (5.3%) associated with non-melanoma skin cancer.
  • Intraepidermal carcinoma (squamous cell carcinoma in situ) was the most common of these (36).
  • There were five basal cell carcinomas (one with intraepidermal carcinoma also) and two invasive squamous cell carcinomas.
  • Twenty-seven of the intraepidermal carcinomas appeared to arise within the seborrhoeic keratosis as did one of the invasive squamous cell carcinomas.
  • Fourteen were clinically diagnosed as a non-melanoma skin cancer with only nine clinically felt to be a seborrhoeic keratosis.
  • Seven were diagnosed clinically as a skin malignancy, whereas three were thought to be solar keratoses.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic. Female. Head. Humans. Male. Medical Records. Middle Aged. Precancerous Conditions. Queensland / epidemiology. Retrospective Studies. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637805.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


84. Perkins W: Who should have Mohs micrographic surgery? Curr Opin Otolaryngol Head Neck Surg; 2010 Aug;18(4):283-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: To review the indications for Mohs micrographic surgery in skin cancer particularly with relationship to tumours of the head and neck and any recent developments which may influence those indications in the near future.
  • RECENT FINDINGS: There is increasing evidence to support the use of Mohs micrographic surgery in the treatment of recurrent and primary basal cell carcinoma and in squamous cell carcinoma, particularly when there is evidence of perineural invasion.
  • Developments in immunohistochemistry with rapid staining of frozen sections may make Mohs micrographic surgery for lentigo maligna and melanoma in situ more feasible in the future, which would be an advantage in the head and neck.
  • [MeSH-major] Mohs Surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Decision Making. Dermatofibrosarcoma / surgery. Histiocytoma, Benign Fibrous / surgery. Humans. Melanoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20613530.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


85. Koch P, Stenzinger A, Viard M, Märker D, Mayser P, Nilles M, Schreiner D, Steger K, Wimmer M: The novel protein PTPIP51 is expressed in human keratinocyte carcinomas and their surrounding stroma. J Cell Mol Med; 2008 Oct;12(5B):2083-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PTPIP51 protein is expressed in all suprabasal layers of normal epidermis, whereas the basal layer contains PTPIP51 mRNA only but lacks the protein.
  • OBJECTIVES: The expression of PTPIP51 was investigated in keratinocyte carcinomas, that is human basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) as well as Bowen's disease (BD) and keratoacanthomas (KAs) on a transcriptional (mRNA) and translational (immunohistochemical) level.
  • To obtain further information about a putative function of PTPIP51, a possible association of PTPIP51 with apoptotic cells, as well as an assumed negative correlation with proliferating cells was investigated by means of an in-situ TUNEL assay and Ki67/MIB-1 antigen staining, respectively.
  • RESULTS: PTPIP51-expression was detected in BCCs and SCCs of the skin, as well as in KAs and BD.
  • Both types of keratinocyte carcinoma revealed a specific localization pattern of PTPIP51 in malignant keratinocytes.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratinocytes / metabolism. Mitochondrial Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012732.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Mitochondrial Proteins; EC 3.1.3.48 / FAM82A2 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC4506173
  •  go-up   go-down


86. Venkatesan A: Pigmented lesions of the vulva. Dermatol Clin; 2010 Oct;28(4):795-805
MedlinePlus Health Information. consumer health - Vulvar Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given the risk of melanomas and pigmented vulvar intraepithelial neoplasia (squamous cell carcinoma in situ), proper evaluation of vulvar pigmented lesions is critical.
  • [MeSH-major] Condylomata Acuminata / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology. Vulva / pathology. Vulvar Diseases / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Acanthosis Nigricans. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Hyperpigmentation. Keratosis, Seborrheic. Melanoma / diagnosis. Melanoma / pathology. Melanosis. Pigmentation Disorders

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20883921.001).
  • [ISSN] 1558-0520
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


87. Gudjonsson JE, Aphale A, Grachtchouk M, Ding J, Nair RP, Wang T, Voorhees JJ, Dlugosz AA, Elder JT: Lack of evidence for activation of the hedgehog pathway in psoriasis. J Invest Dermatol; 2009 Mar;129(3):635-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent reports have suggested that the hedgehog (Hh) pathway is activated in lesional psoriatic skin, and that treatment with the Hh pathway antagonist cyclopamine may lead to rapid resolution of the disease.
  • To assess Hh pathway activity in psoriasis, we isolated RNA from lesional and uninvolved skin of 58 psoriatic patients, and from 63 normal control subjects, and subjected these samples to global gene expression profiling on Affymetrix HU133 Plus 2.0 gene arrays.
  • The microarray data demonstrated downregulation of PTCH1 expression in uninvolved and lesional skin (1.1-fold and 2-fold, respectively; P<0.0001).
  • Additionally GLI1 mRNA was downregulated in lesional skin (1.7 fold; P<0.05).
  • No significant changes were observed between lesional and uninvolved skin for the Hh ligands or Smoothened.
  • In situ hybridization for GLI1 and PTCH1 was positive in basal cell carcinoma tumor cells, but was negligible in uninvolved or lesional psoriatic skin.
  • The absence of elevated Hh target gene expression in lesional psoriatic skin indicates that the Hh pathway is not activated in this disease, raising questions regarding the proposed use of Hh antagonists as antipsoriatic agents.

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2000 Aug 15;224(2):440-52 [10926779.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11873-80 [12917489.001]
  • [Cites] Hum Mol Genet. 2001 Aug 15;10(17):1793-805 [11532989.001]
  • [Cites] J Immunol. 2002 Aug 15;169(4):1869-75 [12165511.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5451-7 [12421920.001]
  • [Cites] Trends Cell Biol. 2002 Dec;12(12):562-9 [12495844.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2173-8 [14633591.001]
  • [Cites] Clin Exp Immunol. 2004 Jan;135(1):1-8 [14678257.001]
  • [Cites] Dermatology. 2004;209(2):81-3 [15316158.001]
  • [Cites] Dermatology. 2004;209(2):126-31 [15316166.001]
  • [Cites] Br J Dermatol. 2004 Sep;151(3):600-7 [15377346.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):353-6 [8896571.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):357-60 [8896572.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):71-6 [10508856.001]
  • [Cites] Nat Med. 2005 Jan;11(1):43-9 [15592573.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):37-42 [15656798.001]
  • [Cites] J Invest Dermatol. 2005 Jun;124(6):1275-83 [15955104.001]
  • [Cites] J Invest Dermatol. 2005 Jun;124(6):1284-92 [15955105.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):181-92 [15978322.001]
  • [Cites] Nat Rev Immunol. 2005 Sep;5(9):699-711 [16138103.001]
  • [Cites] Dev Cell. 2005 Dec;9(6):855-61 [16326396.001]
  • [Cites] Br J Dermatol. 2006 Apr;154(4):619-23 [16536802.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):718-20 [16546599.001]
  • [Cites] Cutis. 2006 Sep;78(3):185-8 [17036662.001]
  • [Cites] Nat Rev Genet. 2006 Nov;7(11):841-50 [17047684.001]
  • [Cites] Int Immunol. 2006 Dec;18(12):1627-36 [17005629.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] Genes Immun. 2007 Jan;8(1):1-12 [17093502.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Curr Top Dev Biol. 2003;53:1-114 [12509125.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] EMBO J. 2003 Jun 2;22(11):2741-51 [12773389.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • (PMID = 18754037.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR052889-02; United States / NIAMS NIH HHS / AR / R01 AR054966; United States / NIAMS NIH HHS / AR / AR052889; United States / NIAMS NIH HHS / AR / R01 AR052889-02; United States / NIAMS NIH HHS / AR / R01 AR045973-10; United States / NIAMS NIH HHS / AR / R01 AR045973; United States / NIAMS NIH HHS / AR / R01 AR052889; United States / NIAMS NIH HHS / AR / AR045973-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0 / patched receptors
  • [Other-IDs] NLM/ NIHMS112832; NLM/ PMC2771222
  •  go-up   go-down


88. Flynn TC: Use of intraoperative botulinum toxin in facial reconstruction. Dermatol Surg; 2009 Feb;35(2):182-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This retrospective analysis assessed the use of intraoperative botulinum toxin type A or B in patients undergoing surgical reconstruction after Mohs micrographic surgery for treatment of skin cancer.
  • Patients had excellent apposition of wound edges and smooth skin overlying soft tissue; no significant complications were noted.
  • Healing of erbium laser ablation did not differ between botulinum toxin type A-treated skin and control skin.
  • Intradermal botulinum toxin type A demonstrated no primary effect on healing of erbium laser-resurfaced skin.
  • [MeSH-major] Botulinum Toxins / administration & dosage. Botulinum Toxins, Type A / administration & dosage. Facial Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma in Situ / surgery. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Humans. Intraoperative Care. Laser Therapy / methods. Male. Middle Aged. Mohs Surgery. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Botox.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215253.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Y70779M1F / rimabotulinumtoxinB; EC 3.4.24.69 / Botulinum Toxins; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


89. Babilas P, Schreml S, Landthaler M, Szeimies RM: Photodynamic therapy in dermatology: state-of-the-art. Photodermatol Photoimmunol Photomed; 2010 Jun;26(3):118-32
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy (PDT) has become an established treatment modality for dermatooncologic conditions like actinic keratosis, Bowen's disease, in situ squamous cell carcinoma and superficial basal cell carcinoma.
  • Aesthetic indications like photo-aged skin or sebaceous gland hyperplasia complete the range of applications.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584250.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  •  go-up   go-down


90. McCluggage WG, Jamison J, Boyde A, Ganesan R: Vulval intraepithelial neoplasia with mucinous differentiation: report of 2 cases of a hitherto undescribed phenomenon. Am J Surg Pathol; 2009 Jun;33(6):945-9
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As far as we are aware, mucinous differentiation has not been described in VIN, although mucinous metaplasia has rarely been reported in non-neoplastic vulval skin and in cutaneous squamous cell carcinoma in situ at extravulval sites.
  • Other possible differential diagnoses include Pagetoid squamous cell carcinoma in situ (Pagetoid VIN), basal cell carcinoma with sebaceous differentiation, and VIN involving skin appendage structures.
  • [MeSH-major] Carcinoma in Situ / pathology. Mucins / metabolism. Papillomavirus Infections / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Differentiation. Cervical Intraepithelial Neoplasia / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Diagnosis, Differential. Female. Human papillomavirus 16. Humans. Neoplasms, Second Primary / metabolism. Neoplasms, Second Primary / pathology. Paget Disease, Extramammary / metabolism. Paget Disease, Extramammary / pathology. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19238078.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Mucins
  •  go-up   go-down


91. Resnik KS, DiLeonardo M: Incidental granular parakeratotic cornification in carcinomas. Am J Dermatopathol; 2007 Jun;29(3):264-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma / pathology. Keratinocytes / pathology. Keratoacanthoma / pathology. Neoplasms, Radiation-Induced / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Cytoplasmic Granules / pathology. Female. Humans. Male. Middle Aged. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519624.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Rausch D, Angermeier M, Capaldi L, Wharton G, Lawrence WD, Robinson-Bostom L: Multinucleated atypia of the vulva. Cutis; 2005 Feb;75(2):118-20
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multinucleated atypia of the vulva (MAV) is an entity with a distinctive histologic pattern of multinucleation in the basal and middle layers of the squamous epithelium that may mimic human papillomavirus (HPV)-related squamous atypias.
  • Results of histopathologic examination revealed a focal area of multinucleation in the basal to middle epithelial layers of the vulvar squamous epithelium, accompanied by mild hyperkeratosis and chronic inflammation.
  • HPV was not identified in the lesion by in situ hybridization techniques.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Lichen Sclerosus et Atrophicus / pathology. Papillomavirus Infections / pathology. Skin / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. Postmenopause. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773533.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. King R, Page RN, Googe PB, Mihm MC Jr: Lentiginous melanoma: a histologic pattern of melanoma to be distinguished from lentiginous nevus. Mod Pathol; 2005 Oct;18(10):1397-401
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical lentiginous melanocytic proliferations in elderly patients continue to pose a diagnostic dilemma with lesions variably categorized as dysplastic nevus, atypical junctional nevus, melanoma in situ (early or evolving) and premalignant melanosis.
  • The clinical diagnosis was variable and included lentigo maligna, atypical nevus, pigmented basal cell carcinoma, seborrheic keratosis and lentigo.
  • [MeSH-major] Dysplastic Nevus Syndrome / diagnosis. Hutchinson's Melanotic Freckle / diagnosis. Lentigo / diagnosis. Melanoma / diagnosis. Nevus, Pigmented / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976811.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Koo BH, Hurskainen T, Mielke K, Aung PP, Casey G, Autio-Harmainen H, Apte SS: ADAMTSL3/punctin-2, a gene frequently mutated in colorectal tumors, is widely expressed in normal and malignant epithelial cells, vascular endothelial cells and other cell types, and its mRNA is reduced in colon cancer. Int J Cancer; 2007 Oct 15;121(8):1710-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ADAMTSL3/punctin-2, a gene frequently mutated in colorectal tumors, is widely expressed in normal and malignant epithelial cells, vascular endothelial cells and other cell types, and its mRNA is reduced in colon cancer.
  • Here, we used in situ hybridization to validate ADAMTSL3 antibodies for IHC of a variety of normal and malignant tissues, including colon cancer.
  • Quantitative real-time PCR (RTQ-PCR) was used to compare mRNA expression levels in colon carcinoma (n = 10) and adjacent normal colon.
  • ADAMTSL3 is expressed in epithelial cells of the colon, fallopian tube, skin, breast, prostate, epididymis, liver, pancreatic islets and bile ducts, as well as by vascular endothelial cells, smooth muscle cells, fibroblasts, cortical and ganglionic neurons and cardiac myocytes.
  • Malignant epithelial cells in colon cancer, as well as breast, prostate, renal and skin tumors expressed ADAMTSL3.
  • Normal colon showed stronger immunostaining of surface than basal crypt epithelium and staining of a variety of cells within the lamina propria and submucosa.
  • RTQ-PCR comparison of ADAMTSL3 mRNA in colon carcinoma and adjacent normal colon demonstrated a statistically significant reduction in the tumors, possibly reflecting their decreased stromal content and lack of complete differentiation of tumor samples.
  • [MeSH-minor] Antibodies, Monoclonal. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Male. Polymerase Chain Reaction. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Culture Techniques

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17597111.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR49930; United States / NIAMS NIH HHS / AR / AR50953
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ADAMTSL3 protein, human; 0 / Antibodies, Monoclonal; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger
  •  go-up   go-down


95. Henning JS, Firoz BF: Contribution of dermatologic surgery in war. Dermatol Surg; 2010;36(1):1-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Despite the large contribution by dermatology to military readiness, there have been no published reports regarding dermatologic surgery or skin cancer in the combat environment.
  • OBJECTIVE: To outline the contribution of dermatologic surgery, including skin cancer and benign tumors, to deployed service men and women in Operation Iraqi Freedom.
  • RESULTS: Two thousand six hundred ninety-six patients were seen in the combat dermatology clinic during the 6-month period reviewed; 8% (205/2,696) of the total visits were for skin cancer, and another 129 patients were treated for actinic keratosis.
  • The specific diagnoses were basal cell carcinoma (n=70), in situ and invasive squamous cell carcinoma (n=68), mycosis fungoides (n=1), bowenoid papulosis (n=1), and in situ and invasive melanoma (n=9).
  • Three hundred seven surgeries were performed during the 6-month period (178 skin cancers and 129 benign lesions), and 20 patients were referred for Mohs micrographic surgery.
  • CONCLUSIONS: To the authors' knowledge, this is the first publication regarding skin cancer and dermatologic surgery in the combat setting.
  • [MeSH-major] Dermatology. Iraq War, 2003-2011. Military Medicine. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19912278.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group: Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer; 2009 Jun 1;115(11):2523-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Actinic keratoses (AKs) are established as direct precursors of squamous cell carcinoma (SCC), but there is significant controversy regarding the rate at which AKs progress to SCC.
  • The authors of this report studied a high-risk population to estimate the risk of progression of AK to SCC and to basal cell carcinoma (BCC) and the risk of spontaneous regression of untreated AKs.
  • The risk of progression of AK to primary SCC (invasive or in situ) was 0.60% at 1 year and 2.57% at 4 years.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Disease Progression. Keratosis, Actinic / pathology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382202.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01AR49342; United States / NCI NIH HHS / CA / R01CA106592; United States / NCI NIH HHS / CA / R01CA106807; United States / NCI NIH HHS / CA / R25CA087972
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Investigator] Weinstock MA; Marcolivio K; Weinstock M; Bingham S; DiGiovanna J; Hall R; Naylor M; Taylor JR; Vertrees J; White C; Hall R; Hannah D; Eilers D; Liang T; Sakla N; Kreuger A; Cole G; Jeffes E; Labrador T; Taylor JR; Kirsner R; Kerri JE; Falabela AG; Givens M; Naylor M; Benson MB; Perry L; Kalivas J; Yanni C; Targovnik S; Austin J; Collier S; Collins JF; Bingham S; Calvert B; Connor P; Crigler C; Davis D; Grubb P; Kelly J; Kirk G; Lawson K; Linzy L; Palmer L; Rhoads M; Sather M; Copeland E; Fye C; Gagne W; de Naranjo PG; Messick C; Vertrees J; Piepkorn M; White C; Lew R; Braverman I; Cole B; Kalish R; McLean D; Thiers B
  •  go-up   go-down


97. Trakatelli M, Katsanos G, Ulrich C, Kalabalikis D, Sotiriadis D, Stockfleth E: Efforts to counteract locally the effects of systemic immunosupression: a review on the use of imiquimod, a topical immunostimulator in organ transplant recipients. Int J Immunopathol Pharmacol; 2010 Apr-Jun;23(2):387-96
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The potent systemic immunosuppression therapy necessary to sustain a life-saving solid organ transplant is associated with an increased incidence of various infections including human papillomavirus infection and skin cancers in organ transplant recipients.
  • Imiquimod, a topical agent that functions through local induction of a specific anti-viral or anti-tumor immune response, appears to be a promising therapeutic option that could potentially counteract in situ the effects of systemic immunosupression in this vulnerable group.
  • [MeSH-minor] Animals. Carcinoma, Basal Cell / drug therapy. Humans. Keratosis, Actinic / drug therapy. Sarcoma, Kaposi / drug therapy. Warts / drug therapy

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646334.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; P1QW714R7M / imiquimod
  • [Number-of-references] 60
  •  go-up   go-down


98. Kazakov DV, Zelger B, Rütten A, Vazmitel M, Spagnolo DV, Kacerovska D, Vanecek T, Grossmann P, Sima R, Grayson W, Calonje E, Koren J, Mukensnabl P, Danis D, Michal M: Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome. Am J Surg Pathol; 2009 May;33(5):705-19
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) salivary gland type basal cell adenocarcinoma-like pattern, low-grade (BCAC-LG);.
  • 2) salivary gland type basal cell adenocarcinoma-like pattern, high-grade (BCAC-HG);.
  • 3) invasive adenocarcinoma, not otherwise specified (IAC-NOS); and 4) sarcomatoid (metaplastic) carcinoma.
  • In 1 case of IAC-NOS, an in situ adenocarcinoma was also found, presumed to have evolved from an adjacent adenomatous and atypical adenomatous component.
  • Cases harboring a sarcomatoid carcinoma featured a malignant epithelial component composed of varying combinations of BCAC-HG, BCAC-LG, IAC-NOS, or squamous cell carcinoma, whereas the sarcomatoid component appeared as either a pleomorphic or spindle-cell sarcoma.
  • Patients with sarcomatoid carcinoma had a relatively good survival.
  • Given the morphologic diversity and complexity of the neoplasms in question, we propose using a more specific terminology with the precise description of the neoplasm components, rather than generic and less informative terms such as "spiradenocarcinoma" or "carcinoma ex cylindroma. "
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Multiple Primary / pathology. Salivary Gland Neoplasms / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Australia. Carcinoma, Skin Appendage / pathology. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Chromosomes, Human, Pair 16. Europe. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Metaplasia. Middle Aged. Mutation. Neoplasm Invasiveness. South Africa. Syndrome. Treatment Outcome. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Malignant cylindroma.
  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194280.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


99. Sneddon JB: The contribution of niche-derived factors to the regulation of cancer cells. Methods Mol Biol; 2009;568:217-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In normal adult tissues, paracrine signals that derive from the stem cell niche, or microenvironment, play an important role in regulating the critical balance between activity and quiescence of stem cells.
  • We recently reported that in basal cell carcinoma of the skin and in diverse other solid tumors, fibroblasts that comprise the tumor cell niche are, indeed, molecularly distinct from those that comprise the normal stroma.
  • [MeSH-major] Biological Factors / metabolism. Cell Culture Techniques / methods. Neoplastic Stem Cells / pathology. Stem Cell Niche / pathology
  • [MeSH-minor] Cell Separation. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Fibroblasts / cytology. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. RNA / genetics. RNA / metabolism. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582430.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biological Factors; 0 / GREM1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 63231-63-0 / RNA
  •  go-up   go-down


100. Sui Y, Yang Z, Xiong S, Zhang L, Blanchard KL, Peiper SC, Dynan WS, Tuan D, Ko L: Gene amplification and associated loss of 5' regulatory sequences of CoAA in human cancers. Oncogene; 2007 Feb 8;26(6):822-35
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that the CoAA gene is amplified at the chromosome 11q13 locus in a subset of primary human cancers including non-small cell lung carcinoma, squamous cell skin carcinoma and lymphoma.
  • The CoAA coding and basal promoter sequences are retained within the amplicons but upstream silencing sequences are lost.
  • CoAA positively regulates its own basal promoter in transfection assays.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878147.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098239-03; United States / NCI NIH HHS / CA / R01 CA098239; United States / NHLBI NIH HHS / HL / R01 HL073453; United States / NCI NIH HHS / CA / R01 CA098239-03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Cyclins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins; 0 / RBM14 protein, human; 0 / RNA, Messenger
  •  go-up   go-down






Advertisement